Skip to main content
Erschienen in: Journal of Translational Medicine 1/2019

Open Access 01.12.2019 | Review

Genetic and molecular biology of breast cancer among Iranian patients

verfasst von: Meysam Moghbeli

Erschienen in: Journal of Translational Medicine | Ausgabe 1/2019

Abstract

Abstract

Background, Breast cancer (BC) is one of the leading causes of cancer related deaths in Iran. This high ratio of mortality had a rising trend during the recent years which is probably associated with late diagnosis.

Main body

Therefore it is critical to define a unique panel of genetic markers for the early detection among our population. In present review we summarized all of the reported significant genetic markers among Iranian BC patients for the first time, which are categorized based on their cellular functions.

Conclusions

This review paves the way of introducing a unique ethnic specific panel of diagnostic markers among Iranian BC patients. Indeed, this review can also clarify the genetic and molecular bases of BC progression among Iranians.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
BC
breast cancer
GSTs
glutathione S-transferases
CYP450
cytochrome 450
HSPs
heat shock proteins
ABC
ATP-binding cassette
AMPK
AMP-activated protein kinase
PDEs
phosphodiesterases
cGMP
cyclic guanosine monophosphate
PKG
Protein Kinase G
ICN
intracellular domain of Notch
CTLA-4
cytotoxic T-lymphocyte antigen-4
TGF
transforming growth factor
HER-2
epidermal growth factor 2
EGF
epidermal growth factor
NRP1
neuropilin-1
IGF-1
insulin-like growth factor 1
CA
cytosine–adenine
PI3K
phosphatidylinositol-3 kinase
S1P
sphingosine-1-phosphate
ER
estrogen receptor
PR
progesterone receptor
lncRNA
long non-coding RNAs
HOTAIR
HOX transcript antisense intergenic RNA
ATM
ataxia telangiectasia–mutated
FEN1
flap endonuclease 1
HR
homologues recombination
CTA
cancer-testis antigens
PKA
protein kinase A
WBP2
WW-binding protein 2
ROS
reactive oxygen species
MTHFR
methylenetetrahydrofolate reductase
CSC
cancer stem cells
ALDH
aldehyde dehydrogenase 1
EpCAM
epithelial cell adhesion molecule
SDC1
Syndecan-1

Background

Cancer is the second and third leading cause of deaths in developed and developing countries, respectively [1]. The China, India, and Japan with 59.7% of Asian breast cancer (BC) cases have the highest incidences in Asia [2]. BC is the most common cancer among Iranian females with mean age of between 46 and 49 years old [3]. Unfortunately, it has been shown that the BC mortality rate had a noticeable raising trend in 1990 to 2010 from 0.96 to 4.33 per 100,000 cases [4]. There is a variation about the BC incidence based on geographical districts in Iran in which the central provinces such as Tehran and Isfahan has the highest incidences [5]. Although, Iran is among the low incidence countries in the case of BC, the Iranian patients have lower ages and advanced stage tumors in comparison with another patients in western countries [6]. There are various BC risk factors which can be categorized as genetic and non-genetic. The non-genetic factors are age, life style, early menarche, late menopause, family history, weight, smoking, diet, socioeconomic condition, and air pollution. Age of diagnosis is about 40–50 years in Asian and African patients whereas it is about 60–70 years in Western countries [7, 8]. Ethnic is also important in age of diagnosis in which the black women have lower ages in comparison with the white women (58 vs. 62 years) [9]. Early Menarche/Late Menopause also increases the risk of breast cancer. Delayed pregnancy and decreased period of breastfeeding are also associated with elevated BC risk. Smoking before the menopause increases the risk of BC. There is also a direct correlation between alcohol consumption and BC risk. A regular physical activity and fruits and vegetables consumptions also decreases the BC risk. In the case of genetic risk factors, the BRCA1 and BRCA 2 mutations are among the main factors which are reported and involved in BC [10, 11]. Beside the BRCA family, the variety of genes are also reported during BC progression such as p53 and PTEN tumor suppressors [12, 13]. Members of DNA repair system and cell cycle regulators such as ATM, CHEK2, NBN, PALB2, and RAD50 are also correlated with risk of BC [14]. Late diagnosis in advanced stages of tumor is one of the main reason of high mortality among the BC patients. Therefore, finding new diagnostic markers will improve the early detection and better management of BC among patients. Regarding the differences between populations in the case of genetic factors, it is required to introduce a population specific panel of genetic markers for every population. Despite various studies about the role of different genes in BC progression among Iranians, there is not still any unique panel of markers for the early detection among Iranian patients. Therefore, for the first time in the present study we summarized the significant genetic markers which are reported until now among the Iranian BC patients (Table 1). We categorized these reported markers in different cellular processes based on their cellular functions (Fig. 1).
Table 1
All of the involved markers in BC susceptibility among the Iranian patients
Study (et al.)
Year
Gene
Type
Population
Results
Danesh [17]
2018
miR-218-2, miR-301b
Sporadic
288 Controls
266 Patients
Polymorphism was correlated with BC risk
Heydari [19]
2018
mir-140-3p
Sporadic
40 Controls
40 Patients
Over expression
Parchami Barjui [20]
2017
miR-502
Sporadic
231 Controls
240 Patients
Polymorphism was correlated with BC risk
Omrani [21]
2014
hsa-miR-499
Sporadic
203 Controls
236 Patients
Polymorphism was correlated with BC risk
Hashemi [23]
2016
mir-608
Sporadic
192 Controls
160 Patients
Polymorphism was correlated with BC risk
Savad [26]
2012
miR-342
Sporadic
77 N/Ta
Over expression in ER/PR positive tumors
Mansoori [28]
2016
miR34a, let-7a
Sporadic
45 N/T
Under expression
Saberi [29]
2016
miR-328
Sporadic
28 N/T
Over expression
Damavandi [30]
2016
miR-132, miR-212, and miR-22
Sporadic
36 N/T
Correlation with grade and stage
Nejati-Azar [32]
2018
miR-196a
Sporadic
200 Controls
200 Patients
Polymorphism was correlated with BC risk
Sarrafzadeh [35]
2017
CCAT2
Familial/
Sporadicb
48 N/T
Correlation with stage an lymph node metastasis
Hassanzarei [37]
2017
HOTAIR
Sporadic
231 Controls
220 Patients
Polymorphism was correlated with BC risk
Miri [42]
2012
eRF3a/GSPT1
Familial/
Sporadic
250 Controls
250 Patients
Polymorphism was correlated with BC risk
Hosseini [45]
2011
MTHFR
Sporadic
306 Controls
294 Patients
Polymorphism was correlated with BC risk
Rezaei [46]
2017
MTHFR
Familial/
Sporadic
84 Patients
Polymorphism was correlated with BC risk
Jahangiri [48]
2018
DNMT1, DNMT3A, and DNMT3B
Sporadic
72 Patients
Correlation with grade
Eftekhar [49]
2014
DNMT3B
Sporadic
138 Controls
100 Patients
Polymorphism was correlated with BC risk
Hashemi [51]
2012
CASP8
Sporadic
203 Controls
236 Patients
Polymorphism was correlated with BC risk
Aghababazadeh [52]
2017
CASP8
Familial/
Sporadic
27 N/T
Under expression
Eskandari-Nasab [54]
2015
TP53
Sporadic
203 Controls
236 Patients
Polymorphism was correlated with BC risk
Payandeh [55]
2016
P53
Sporadic
231 Patients
Correlation with grade and lymph node metastasis
Rostamizadeh [58]
2013
BCL-2
Sporadic
40 Patients
Correlation with grade and survival
Golmohammadi [61]
2016
PTEN
Sporadic
100 Patients
Correlation with stage and survival
Sadeq [62]
2011
PTEN
Sporadic
20 Controls
57 Patients
Hypermethylation was correlated with stage and lymph node metastasis
Yari [63]
2016
PTEN
Familial/
Sporadic
50 Controls
103 Patients
Methylation
Ghaffari [64]
2016
BIRC5
Sporadic
40 Patients
Correlation with age
Vallian [70]
2009
p16INK4A
Sporadic
70 Controls
70 Patients
Methylation was correlated with stage
Salimi [72]
2012
ATM and cyclinD1
Sporadic
119 Patients
ATM under expression and cyclinD1 over expression
Mehdipour [73]
2011
ATM
Sporadic
248 Controls
129 Patients
Polymorphism was correlated with BC risk
Amininia [75]
2014
CCNE1
Sporadic
225 Controls
266 Patients
Polymorphism was correlated with BC risk
Hajikhan Mirzaei [78]
2012
DBC2
Sporadic
50 Patients
Methylation
Golmohammadi [79]
2017
AURKA
Sporadic
100 Controls
100 Patients
Polymorphism was correlated with BC risk
Mojgan [80]
2012
ERCC1
Sporadic
126 Controls
300 Patients
Polymorphism was correlated with BC risk
Jalali [83]
2016
XRCC1
Sporadic
200 Controls
100 Patients
Polymorphism was correlated with BC risk
Rezaei [86]
2016
FEN1
Sporadic
225 Controls
266 Patients
Mutation
Madjd [88]
2014
EMSY
Familial/
Sporadic
116 Patients
Correlation with tumor size and lymph node metastasis
Hallajian [91]
2017
ATM, RAD51, and BRCA1
Sporadic
50 Patients
Under expression
Darbeheshti [94]
2018
BRCA1
Sporadic
53 Patients
Correlation with grade and lymph node metastasis
Madjd [95]
2011
BRCA1
Familial/
Sporadic
156 Patients
Correlation with grade
Rezaei [96]
2015
APOBEC3
Sporadic
217 Controls
262 Patients
Mutation
Abbasi [98]
2017
FANCA
Familial/
Sporadic
295 Controls
304 Patients
Mutation
Hashemi [102]
2014
hTERT
Sporadic
225 Controls
266 Patients
Polymorphism was correlated with BC risk
Haghi [108]
2015
HLA-G
Sporadic
255 Controls
227 Patients
Polymorphism was correlated with BC risk
Mahmoodi [109]
2012
HLA-II
Sporadic
80 Controls
100 Patients
Polymorphism was correlated with BC risk
Ghaderi [110]
2001
HLADRB1
Sporadic
36 Controls
36 Patients
Polymorphism was correlated with BC risk
Faghih [113]
2009
IL13
Sporadic
195 Controls
305 Patients
Polymorphism was correlated with BC risk
Khodadadi [119]
2014
IL-27 and IL-23
Sporadic
50 Controls
50 Patients
Over expression
Vahedi [120]
2018
CCR7
Sporadic
70 N/T
Correlation with stage, grade, and lymph node metastasis
Jafarzadeh [123]
2015
CCL22
Sporadic
100 Controls
100 Patients
Correlation with stage
Dayer [124]
2018
CXCR4
Sporadic
36 N/T
Over expression in HER2 positive tumors
Jaberipour [127]
2010
FOXP3 and CTLA-4
Sporadic
40 Controls
55 Patients
Correlation with stage and grade
Hamidinia [128]
2013
FOXP3 and OX40
Sporadic
40 Controls
40 Patients
Correlation with stage
Rostami [134]
2015
Leptin
Sporadic
171 Controls
203 Patients
Polymorphism was correlated with BC risk
Mohammadzadeh [136]
2015
Leptin
Sporadic
100 Controls
100 Patients
Polymorphism was correlated with BC risk
Pornour [140]
2014
DRD2, DRD4
Sporadic
30 Controls
30 Patients
Over expression
Amani [141]
2014
TGFβ1
Sporadic
110 Controls
110 Patients
Polymorphism was correlated with BC risk
Parvizi [142]
2016
TGF-β
Sporadic
100 Controls
100 Patients
Polymorphism was correlated with BC risk
Tabatabaeian [143]
2013
HER-2
Familial/sporadic
15 Controls
80 Patients
Over expression
Panahi [144]
2013
HER-2
Familial
299 Patients
Correlation with ER/PR
Amirifard [145]
2016
HER-2
Familial/sporadic
130 Patients
Correlation with stage and age
Salimi [146]
2016
ERBB4
Familial/sporadic
192 Controls
172 Patients
Polymorphism was correlated with BC risk
Mansouri Bidkani [147]
2018
ERBB4
Familial/sporadic
148 Controls
172 Patients
Polymorphism was correlated with BC risk
Bagheri [148]
2016
ERBB4
Sporadic
146 Controls
146 Patients
Polymorphism was correlated with BC risk
Eskandari-Nasab [152]
2012
NGX6
Sporadic
203 Controls
236 Patients
Under expression
Seifi-Alan [154]
2018
NRP1
Sporadic
48 N/T
Correlation with stage, grade, and lymph node metastasis
Javadi [156]
2012
IGF-1
Familial/sporadic
224 Controls
215 Patients
Mutation
Azizi Tabesh [158]
2017
PIK3CA
Sporadic
80 Patients
Mutation
Sanaei [159]
2017
KRAS
Sporadic
204 Controls
244 Patients
Polymorphism was correlated with BC risk
Nazouri [160]
2017
SPHK1
Sporadic
120 Patients
Correlation with BMI
Heshmatpour [164]
2014
PIK3CA
Sporadic
200 Controls
200 Patients
Polymorphism was correlated with BC risk
Ghalaei [165]
2018
APPL2 and OCC1
Sporadic
30 N/T
APPL2 under expression and OCC1 over expression
Karami-Tehrani [166]
2016
RIP1K and RIP3K
Sporadic
20 Normal
45 Tumor
Correlation with grade
Nikseresht [168]
2010
UBE2Q2
Sporadic
21 N/T
Over expression
Hashemi [170]
2012
GSTM1, GSTT1, GSTP1
Sporadic
152 CONTROLS
134 PATIENTS
Polymorphism was correlated with BC risk
Sharif [171]
2017
GSTO1, GSTO2
Sporadic
150 Controls
153 Patients
Polymorphism was correlated with BC risk
Saadatian [173]
2014
CYP1A1
Sporadic
100 Controls
100 Patients
Polymorphism was correlated with BC risk
Saghafi [174]
2018
CYP2D6
Familial/
Sporadic
84 Patients
Polymorphism was correlated with BC risk
Yazdi [179]
2015
CYP2D6
Sporadic
101 Patients
Polymorphism was correlated with BC risk
Homaei-Shandiz [184]
2016
HSP27
Sporadic
65 Controls
97 Patients
High levels of serum anti Hsp27
Ghafouri [187]
2016
ABCG2
Sporadic
200 Controls
100 Patients
Polymorphism was correlated with BC risk
Estiar [189]
2017
CEACAM19
Sporadic
75 Patients
Over expression
Moazzezy [192]
2014
CA15-3 and CEA
Sporadic
30 Controls
30 Patients
Over expression
Mansouri [193]
2016
MUC1
Sporadic
50 Patients
Over expression
Zarei [196]
2017
CDH1
Sporadic
200 Controls
100 Patients
Polymorphism was correlated with BC risk
Esmaeili [198]
2018
CD44
Familial/
Sporadic
175 Controls
175 Patients
Polymorphism was correlated with BC risk
Sadeghi [202]
2017
EpCAM
Sporadic
122 Patients
Correlation with grade
Taghizadeh-Kermani [204]
2014
CD10
Sporadic
150 Patients
Correlation with grade, lymph node metastasis, and tumor size
Fard [207]
2018
CAV-1
Sporadic
203 Controls
203 Patients
Polymorphism was correlated with BC risk
Mobasheri [208]
2016
SYCP3
Sporadic
47 Patients
Over expression
Malek-Hosseini [209]
2017
SDC1
Familial/
Sporadic
30 Controls
61 Patients
Correlation with tumor size
Karami-Tehrani [213]
2012
PDE5 and PDE9
Sporadic
70 N/T
Correlation with stage, grade, and lymph node metastasis
Karami-Tehrani [215]
2012
PKG
Sporadic
70 N/T
Under expression
Paryan [218]
2016
NOTCH1
Sporadic
20 N/T
Correlation with tumor type
Taghavi [220]
2016
WISP1
Familial/
Sporadic
15 Controls
85 Patients
Correlation with age and tumor size
Madjd [224]
2012
ALDH1
Familial/
Sporadic
127 Patients
Correlation with BRCA1
Jahangiri [229]
2018
PAX2
Sporadic
72 Patients
Correlation with survival
Estiar [233]
2017
NDRG3
Sporadic
6 Normal
88 Tumor
Correlation with survival
Hosseini [234]
2014
ERα
Sporadic
10 Normal
19 Tumor
Over expression
Abbasi [235]
2013
ERα
Familial/
Sporadic
147 Controls
150 Patients
mutation
Farzaneh [236]
2016
CYP19
Sporadic
135 Controls
134 Patients
Polymorphism was correlated with BC risk
Kamali-Sarvestani [241]
2005
TNF-α
Sporadic
160 Patients
Polymorphism was correlated with BC risk
Vakil Monfared [245]
2018
TNFSF4
Sporadic
126 Controls
123 Patients
Polymorphism was correlated with BC risk
Colagar [250]
2015
VDR
Sporadic
127 Controls
134 Patients
Microsatellite
Zhalehjoo [255]
2017
CYP24A1 and CYP27B1
Sporadic
30 N/T
Correlation with stage and age
Shahabi [256]
2018
VDR
Familial/
Sporadic
214 Controls
203 Patients
Polymorphism was correlated with BC risk
Shahbazi [257]
2013
VDR
Sporadic
156 Controls
140 Patients
Polymorphism was correlated with BC risk
Ebrahimi [260]
2017
CYP17
Familial/
Sporadic
205 Patients
Polymorphism was correlated with BC risk
Esmaeili [263]
2015
AKAP3
Sporadic
162 N/T
Correlation with stage and tumor size
Nourashrafeddin [266]
2015
WBP2NL
Sporadic
30 Normal
50 Tumor
Over expression
Rastgoosalami [267]
2016
MAGE-1
Sporadic
113 Patients
Correlation with lymph node metastasis and tumor size
Dianatpour [268]
2012
TSGA10
Sporadic
50 Patients
Expression
Kazemi-Oula [272]
2015
ODF4 and RHOXF2
Familial/Sporadic
40 N/T
Over expression
Arezi [278]
2018
ND4
Sporadic
28 Normal
60 Tumor
Mutation
Ghaffarpour [282]
2014
ATPase6
Sporadic
49 Patients
Mutation
aTumor tissues and normal margins
bBoth of familial and sporadic patients among cases

Main text

Non coding RNAs and epigenetic modifications

MiRNAs as short non-coding RNAs can regulate gene expression post-transcriptionally through 3-UTR in the target mRNAs which are involved in various cellular functions including apoptosis and cell proliferation [15]. MiRNAs polymorphisms can change the function of miRNAs through modulation of their expression, processing, or binding sequences [16]. It has been observed that there was a significant correlation between rs11134527 variant in miR-218-2 and rs384262 variant in miR-301b and higher risk of BC among a sub population of Iranian patients [17]. SOX2 self renewal factor is one of the targets of miR-140 and miR-140/SOX2 interaction can be associated with cell survival in BC [18]. Another group also evaluated the serum levels of miR-140-3p expression in Iranian BC patients compared with healthy cases. They showed significant miR-140-3p over expression in BC in comparison with the normal cases. Moreover, there was a correlation between mir-140-3p expression and age, in which the premenopausal and ≤ 48 years old female with BC have shown mir-140-3p over expression. They introduced this marker as a diagnostic factor in premenopausal and in ≤ 48 years old females with BC [19]. BRCA1/BRCA2 are the targets of MiR-146a. It has been shown that the miR-146a is involved in BC. Moreover, there was a significant correlation between rs16917496 of miR-502 and higher risk of BC among a sub population of Iranian patients [20]. It has been shown that there was a correlation between hsa-miR-499 rs3746444 CC and C genotypes and high risk of BC among a subpopulation of Iranian subjects [21]. Mir-608 targets several factors such as INSR, IL-1A, GHR, and TP53 which are involved in tumor growth and apoptosis [22]. It has been observed that there was a significant correlation between rs4919510 polymorphism and BC, in which such polymorphism significantly decreased the BC susceptibility among a sub population of Iranian BC patients [23]. MiR-21 is involved in regulation of cell proliferation and apoptosis through targeting various factors such as PTEN and PDCD4 [24, 25]. Another study also showed that there was a high levels of miR-21 expression in aggressive breast tumors. Moreover, a significant under expression of miR-205 was observed in ER/PR/HER2 negative breast tumors compared with normal samples. The miR-342 under and over expressions were also observed in ER/PR negative and ER/PR positive BC tissues respectively in an Iranian population [26]. Although, MiR-34a and let-7 are as tumor suppressors are observed in normal cells, their under expression is also observed in tumors. MiR-34a is one of the targets of p53. MiR-34a also targets the BCL2 and caspase 3 [27]. It has been reported that the p53, miR34a, and let-7a were significantly down regulated in BC in comparison with normal samples, however, BCL2 was up regulated in a sub population of Iranian patients [28]. MiR-328 inhibits the BCRP/ABCG2 expression which is an ABC transporter protein involved in cellular defence and multi-drug resistance. It has been observed that the tumor tissues had higher levels of miR-328 expression in comparison with normal margins among a sub population of Iranian BC patients [29]. Significant miR-132/miR-212 downregulation and miR-22 upregulation were reported in BC samples compared with corresponding normal margins among Iranian cases. Moreover, highgrade samples had decreased expression of miR-132, miR-212, and miR-22, whereas the advanced stage (III) tumors had increased expression of these markers [30]. HOX10 transcription factor is one of the targets of mir196a2 [31]. It has been shown that the miR-196a expression in BC patients harboring C/C rs11614913 was higher than that in the cases with TT genotype. The rs11614913 polymorphism was introduced an early detection marker among a sub population of Iranian BC patients [32]. Long non-coding RNAs (lncRNA) are a class of transcripts longer than 200 nucleotides. Beside the aberration in coding RNAs, the deregulation of lncRNA is also related with tumor progression. They exerts their post-transcriptional regulatory functions through interaction with DNA, RNA, and protein molecules. CCAT2 is a lncRNA that exerts its oncogenic function through regulation of WNT/β-catenin pathway [33, 34]. It has been shown that there was lower levels of CCAT2 expression in tumor tissues compared with normal margins in a group of Iranian BC patients. Moreover, significant converse correlations were also observed between CCAT2 expression, stage, and lymph node involvement in which the early stage tumors without metastatic lymph nodes had higher levels of CCAT2 expression [35]. HOX transcript antisense intergenic RNA (HOTAIR) is also a lncRNA, which binds to LSD1 and PRC2 to promote HOXD repression through histone modification and chromatin remodeling [36]. It has been shown that the HOTAIR rs920778 and rs12826786 polymorphisms were significantly correlated with high risk of BC, and rs1899663 variant also showed a significant correlation with low risk of BC among a sub population of Iranian cases [37]. Therefore, HOTAIR have probably an important role in BC progression via polycomb complexes and can be introduced as efficient prognostic and diagnostic marker for the BC. Deregulation of translation machinery and ribosome biogenesis are common features of tumor cells in post transcriptional level and epigenetic. eRF1 and eRF3 are the main terminators in eukaryotic translation process, in which the RF3 functions as an enhancer of RF1 through GTPase activity [38]. Moreover, RF3 is involved in poly (A) tail stabilization via interaction with PABP [39]. RF3 has two isoforms including RF3a and RF3b that are encoded by eRF3a/GSPT1 and eRF3b/GSPT2 genes, respectively [40, 41]. The association between the GGC repeat polymorphism in exon 1 of eRF3a/GSPT1 and the potential genetic susceptibility for BC progression was evaluated among a sub population of Iranian subjects. It has been shown that the Iranian patients harboring the 12-GGC and 7-GGC alleles of eRF3a/GSPT1 have a high risk of BC. Moreover, the homozygote 7-GGC repeat can be correlated with the age of BC progression among a sub population of Iranian females [42]. The tumor progression is related with genetic and epigenetic changes. DNA methylation is one of the most important epigenetic mechanism during the neoplastic transformation. Role of DNA methylation in tumorigenesis is mainly related to the promoter hypomethylation and hypermethylation of oncogenes and tumor suppressor genes respectively. Methylenetetrahydrofolate reductase (MTHFR) regulates folate metabolism, DNA methylation, synthesis, and repair [43, 44]. There is probably a correlation between MTHFR 1298AA and 677CC genotype and higher risk of BC. Moreover, the frequency of MTHFR 677 CT, TT and 1298 CT, AA variants in BC patients were lower than that in the healthy controls in an Iranian population [45]. It has been also observed that the C677T TT variant of MTHFR was significantly correlated with elevated risk of familial BC in Iranian patients [46]. Tamoxifen has been used as a treatment option for hormone responsive breast tumors. However, about onethird of patients are resistant and face with relapse [47]. The expression of DNMT1, DNMT3A, and DNMT3B DNA methyltransferases in tamoxifen resistant patients were higher than that in the tamoxifen sensitive Iranian BC patients. There were significant associations between their protein expression and tumor grade, and also DNMT3B expression and lymph node metastasis in tamoxifen sensitive group. There was significant correlation between DNMT3A and DNMT3B expression and high histologic grade in tamoxifen resistant group. Generally they showed that the DNMTs overexpression has a negative association with survival in Iranian tamoxifen-treated BC cases [48]. Another group showed that, the DNMT3B 149 C → T polymorphism was significantly associated with reduced BC risk among patients in Southern Iran [49].

Apoptosis, DNA repair, and cell cycle

Apoptosis is a critical process through the organ development and is a defense mechanism against deregulated cell proliferation and tumorigenesis. It includes several pathways such as extrinsic and intrinsic. Death receptors are the activators of extrinsic pathway which subsequently activates the caspase-8. Then, the caspase-8 initiates a cascade by cleaving caspase-3, caspase-7, or Bid [50]. A group evaluated the probable association between CASP8 6N del variant and BC susceptibility in Iranian patients. They showed that there was a significant higher frequency of del allele in the control group compared with BC cases, which highlights the anti tumori role of the CASP8 −652 6N del variant among Iranian BC cases [51]. Another group also assessed the levels of CASP8 expression in tumor in comparison with normal margins of Iranian BC patients, which showed decreased CASP8 expression in tumour tissue. Moreover, there was a significant correlation between CASP8 expression and HR status [52]. TP53 as a tumor suppressor regulates the cell cycle and apoptosis [53]. It was shown that the TP53 16-bp INS/DEL polymorphism can be associated with risk of BC among a sub population of Iranian patients [54]. There was also significant correlations between p53 expression, lymph node involvement, age, and tumor grade in Kurdish BC patients in Western Iran [55]. The mitochondrial pathway of apoptosis process is associated with BCL-2 which is also a prognostic factor in BC for its relation with defence mechanisms against the genotoxic damages [56, 57]. It has been observed that there was higher levels of BCL-2 mRNA expression in tumors compared with normal margins in a sub population of Iranian BC subjects. BCL-2 over expression was positively associated with tumor grade and ER/PR, and negatively with tumor size. There was also a significant correlation between high levels of BCL-2 mRNA expression and survival rates [58]. PTEN is a tumor suppressor via the stimulation of apoptosis in tumor cells and suppression of cell proliferation. Moreover, It is a negative regulator of intracellular PIP3 and AKT/PKB signaling pathway. PTEN regulates the p53 stability through AKT-MDM2 pathway or direct interaction [59]. Moreover, PTEN-p300 complex maintains P53 acetylation following the DNA damage [60]. A significant correlation between PTEN expression and stage has been reported among a group of Iranian BC patients, in which advanced stage tumors had lower levels of PTEN expression. Moreover, the tumors without PTEN expression had lower survival rates compared with tumors with PTEN expression, which can be introduced as a prognostic marker [61]. It has been observed that the majority of BC patients had PTEN promoter methylation which was not observed among the normal cases. Moreover, there was a correlation between PTEN hypermethylation and lymph node metastasis and advanced stages tumors among a sub population of Iranian patients [62]. Another study have reported there was association between PTEN promoter methylation and BC susceptibility among a sub population of Iranian patients [63]. BIRC5 is an anti apoptotic factor and cell cycle regulator which is only expressed at the embryonic stage. It has been reported that the BIRC5 is associated with early onset BC progression, in which there was a significant correlation between BIRC5 up regulation and Iranian patients who were younger than 40 years [64].
DNA repair and cell cycle regulation are important processes related to the cancer susceptibility and chemotherapeutic responses. Cell proliferation is regulated by signaling pathways to limit the proliferation in adequate ratio. The cell cycle is regulated by several factors such as cyclins, CDK, and CDKIs. G1 to S progression is related with cyclin D and CDK 4/6, which is repressed by INK4 family [65]. P16INK4A is belonged to the INK4 family [66], and its deregulation has been reported in different tumors [67]. The p16INK4A is responsible for the G0 and G1 cell cycle arrest through suppression of cyclin D–CDK4/6, and it also has a critical role as an inhibitor of pRb phosphorylation [68, 69]. It has been reported that there was a correlation between p16INK4A promoter methylation and primary BC, in which the hypermethylated cases were in primary tumors with stages of I, II and III. Therefore, they concluded that the p16INK4A promoter methylation can be introduced as an efficient marker of early detection among a sub population of Iranian sporadic BC patients [70]. Cyclin D1 is one of the main cell cycle regulators that binds with CDK4/6 to phosphorylate pRb through the cell cycle. The ataxia telangiectasia-mutated (ATM) is also involved in DNA damage recognition [71]. A study has evaluated the ATM and cyclin D1 expression in a sub population of Iranian BC patients. They showed about 21.6% of cyclin D1 under-expression which were mostly in HER-2–positive tumors. In the case of ATM, about 50% had ATM under-expression. The levels of ATM expression in normal margins were lower than normal controls which can be related to the epigenetic regulation of ATM expression. Therefore, they concluded that the ATM and cyclin D1 under and over expressions respectively can be associated with tumor progression among the Iranian BC patients [72]. It has been observed that there was a significant difference of D1853N ATM polymorphism between patients and healthy controls, introducing this polymorphism as a diagnostic marker among a sub population of Iranian cases [73]. Cyclins and CDKs activate the E2F transcription factor through inhibition of retinoblastoma protein. Cyclin E/CDK2 complex is associated with DNA replication and chromosomal stability [74]. A correlation between CCNE1 rs1406 C/A polymorphism and elevated risk of BC has been shown among an Iranian population in southeast of Iran [75]. DBC2 inhibits cell proliferation via CCND1 down-regulation [76], and is associated with ubiquitination, cell cycle, and apoptosis [77]. Methylation status of DBC2 promoter sequence was assessed in blood and BC tissue samples of an Iranian sub population, showed a correlation between aberrant DBC2 methylation and tumor progression in sporadic cases [78]. The AURKA is involved in cell cycle regulation, G2/M transition, centrosome division, and genomic instability. It has been observed that the BC cases had higher frequency of Ile/Ile variant at F31I locus of AURKA in comparison with the healthy cases. Moreover there was significant correlation between Ile/Ile F31I polymorphism and stage of BC among a sub population of Iranian patients [79]. ERCC1 as a member of nucleotide excision repair system is vital for the genome integrity. Association between ERCC1 C8092A and BC was assessed and showed a correlation between T/T of ERCC1 genotype and increased risk of BC among a sub population of Iranian patients [80]. XRCC1 is one of important factors in base excision repair to maintain the DNA against the carcinogens and oxidative species [81, 82]. It has been reported that the Arg194Trp XRCC1 polymorphism was more frequent among patients compared with normal cases. Moreover, this variant was also correlated with stage. They introduced the Trp194 allele of XRCC1 as a risk factor among Iranian Kurdish BC patients [83]. Flap endonuclease 1 (FEN1) tumor suppressor is a critical factor in DNA replication, repair, and genome stability [84]. It is involved in base–excision repair and formation of Okazaki fragments during DNA replication [85]. There was a correlation between FEN1 haplotypes and BC susceptibility among a sub population of Iranian patients in Southeastern Iran [86]. BRCA family mediates double stranded DNA break repairs and chromatin remodeling [87]. EMSY is an inhibitor of the BRCA2 transactivity. It has been shown that the majority of a group of Iranian BC patients had EMSY protein expression. The sporadic cases had higher levels of EMSY expression compared with familial cases. There was a direct correlation between EMSY expression, larger tumor size, higher relapse, and increased lymph node involvement [88]. Homologues Recombination (HR) is one of the main processes during the DSB repair. RAD51 is a key factor in HR regulation. DSB activates the ATM that subsequently phosphorylate and activate the BRCA1 which is associated with RAD51 [89, 90]. It has been shown that there were significant ATM, RAD51, and BRCA1 down regulations in BC tissues compared with normal margins in a sub population of Iranian subjects. ATM under expression was significantly correlated with tumor stage, vascular invasion, and malignant behavior. Down regulation of RAD51 was also significantly correlated with lymph nodes metastasis, age, and grade of tumor [91]. BRCA1 is a nuclear phosphoprotein involving in DSB repair, cell cycle regulation, and apoptosis [92, 93]. There was significant correlations between BRCA1 downregulation, high grade, and lymph node metastasis. Low levels of BRCA1 expression were observed in majority of triple-negative and luminal tumors in comparison with normal tissues among a sub population of Iranian cases [94]. The altered BRCA1 expression is more frequent in primary BC, and loss or decreased BRCA1 expression in high-grade were more frequent in comparison with differentiated tumors. Moreover, there was a significant inverse association between the levels of BRCA1 and CD44 expressions in Iranian BC patients [95]. APOBEC3 is a cytidine deaminase involved in RNA editing, cell cycle regulation, and repression of the retrovirus replication. It has been observed that the APOBEC3 deletion had a significant correlation with increased risk of BC among a sub population of Iranian cases [96]. The FANCA is a tumor suppressor related to DNA repair [97]. Duplication in FANCA promoter sequence can be associated with increased risk of BC among Iranian cases [98]. Telomeres are repeated sequences at the end of linear chromosomes to maintain them against the loss of genetic information through the cell proliferation [99]. Telomere shortening leads the cells up to the senescence and apoptosis, which is an intra cellular defence mechanism against genomic instability and tumorigenesis [100]. hTERT is the main subunit of telomerase complex to maintain the telomere stability [101]. The hTERT rs2736098 variant increased the risk of BC in a subpopulation of Iranian patients in southeast Iran [102].

Immune response

The immune system is able to find tumor cells through tumor-specific antigens or other induced factors by cellular stress [103]. However the microenvironment changes by tumor cells can be resulted to tumor escape from immune response [104]. HLA system has important role in tumor antigen presentation for the immune system [105, 106]. HLA-G has immunosuppressive functions during the tumor progression [107]. A mutational analysis on a sub population of BC patients in northwestern-Iran showed a slightly higher allele frequency of HLA-G 14 bp deletion among patients. It seems that the high HLA-G expression induces tumor cells toward progressive stages. They concluded that the HLA-G 14 bp InDel polymorphism is probably a risk factor of BC progression among this population [108]. HLA-l and 2 present the antigens to the CD8 + T and CD4 + T cells, respectively. HLA-DRB1/DQB1 and HLA-DQA1 are belonged to the HLA-2 beta and alpha chains paralogues, respectively. It has been shown that the HLA-DQA1*0301 variant is correlated with elevated risk of early onset BC progression. Whereas, the HLADQA1*0505 and HLA-DQB1*0602 variants were associated with decreased risk of BC among young patients. They concluded that the HLA-II polymorphisms are risk factors of BC among a sub population of Iranian patients [109]. It has been observed that there was a significant association between HLADRB1* 12 allele and risk of BC among a sub population of Iranian patients [110]. Interleukin-13 is mainly secreted by activated TH2 lymphocytes and Natural Killer T cells [111, 112]. It has been shown that there was a correlation between CCA and ACA haplotypes of IL13 gene and risk of BC. Moreover, −1512C and −1055C alleles are involved in BC progression among a sub population of Iranian patients [113]. IL-27 is a heterodimeric cytokine comprising of EBI3 and P28 subunits that induces the CD4 + T cell proliferation through activation of STAT1 and 3 transcription factors [114, 115]. Moreover, IL-27 in association with TGF-β has a critical function in generation of IL-10-producing Tr1 cells [116]. IL-23 also regulates the memory CD4 + T cells proliferation through STAT3 activation [117, 118]. It has been reported that there was significantly higher levels of IL-27 and IL-23 expressions in BC peripheral bloods compared with normal cases, which can be introduced for the immunotherapy in Iranian BC patients [119]. CCR7 chemokine receptor is a G-protein coupled receptor involved in migration of immune cells to the lymphoid organs. It has been observed that the CCR7 expression was significantly associated with lymph node involvement, garde, and stage. Therefore, they introduced CCR7 as a prognostic marker among a sub population of Iranian BC patients [120]. CCL22 chemokine is produced by macrophages and DCs following the activation with microbial infection or CD40. The CCL22 production is regulated by Th1/2 cytokines such as IL-4, IL-5, and IFN-γ [121]. Therefore, CCL22 is associated with Th2- and Treg cells through inhibition of the immune responses against microbial infections and cancer cells [122]. It has been shown that the BC patients had significantly higher serum levels of CCL22 compared with healthy cases. There was also a direct correlation between the levels of CCL22 expression and stage of tumor. The frequencies of CC and C genotypes at rs223818 of CCL22 were significantly higher in BC patients in comparison with normal cases. Carriers of such genotypes also had higher serum levels of CCL22 compared with cases harboring GG or G variants, which highlighted the role of SNP rs223818 in BC risk via upregulation of the CCL22 [123]. CXCL12 is a chemokine that binds to its receptor (CXCR4) to activate MAPK1/MAPK3 through intracellular calcium ion which is involved in migration and adhesion. It has been shown that there was a correlation between HER2 and CXCR4 expression in a group of Iranian BC patients in which the HER2 positive tumors significantly had higher levels of CXCR4 expression in comparison with the HER2 negative tumors. They suggested the HER2 as probable inducer of CXCR4 among BC patients [124]. T-regulatory cells express cytotoxic T-lymphocyte antigen-4 (CTLA-4) and FoxP3 transcription factor [125, 126]. It has been shown that there was higher levels of FOXP3 and CTLA-4 mRNA expressions in blood samples of early stage and low grade BC patients compared with healthy subjects in an Iranian population. They highlighted the importance of regulatory T cells inhibitory mechanisms through the tumor progression which prepares opportunity for the tumor cells to hide from immune system [127]. A significant correlation has been also reported between FOXP3 and OX40 expressions and tumor stage in peripheral blood samples of Iranian BC patients [128]. Obesity is one of the main socio-epidemiological health problems globally and a negative BC prognostic factor [129]. The high ratio of adipose tissue increases the risk of tumor relapse in BC [130]. Negative effect of obesity on BC survival is associated with inflammatory cytokines such as leptin and IL-6 which are secreted by adipose tissue [131]. Leptin is an adipocytokine which is important in tumor progression through the activation of AKT signaling pathway [132]. Leptin is involved in cell proliferation, migration, and survival via regulation of various factors such as AP1, ERK2, and MAPK [133]. It has been reported that the leptin G-2548A (rs7799039) polymorphism was significantly correlated with risk of BC among a sub population of Iranian patients. They concluded that the females harboring AA genotype have an earlier menarche age and higher risk of breast cancer [134]. It has been also shown that the obese BC had higher serum leptin concentration compared with non-obese Iranian BC cases. Therefore, the inflammation has a key function in distant metastasis, since the adipose is the main source of leptin the weight loss through the physical activity can be an efficient option to decrease the negative role of leptin in BC progression [135]. LEP-2548G/A frequency was evaluated and showed the Iranian patients harboring LEP-2548G variant had a noticeable increased risk of BC [136]. Chronic stress is involved in tumorigenesis through secretion of neurotransmitters like during lymphocyte migration and angiogenesis. Dopamine is a neurotransmitter which has proliferative effects and induces the T cells for secretion of anti immune cytokines [137]. Dopamine receptors are from G-protein family which play important roles to induce or suppress intracellular cAMP [138]. The stress can alter dopamine receptor expression. Dopamine receptors (DRD1-DRD5) are categorised into D1 (stimulatory receptors) and D2 (inhibitory receptors) families [138, 139]. It has been reported that there was significantly higher levels of DRD2-DRD4 in a group of Iranian BC cases compared with healthy controls [140]. The transforming growth factor (TGF)-β is a pleiotropic cytokine expressed in several cells including peripheral blood mononuclear cells and platelets that plays critical roles in regulation of cell proliferation, apoptosis, and angiogenesis. The TGF-beta superfamily are involved in cell proliferation through activation of SMAD transcription factors. It has an anti cancer function in normal cells, whereas it promotes the tumor progression in advanced stage tumors. It has been observed that there was a significant difference in frequency of TGFβ1 “GTGCCGC” haplotype between BC and healthy controls among an Iranian population [141]. Moreover, it has been shown that there was significant correlations between TT and AA genotype of −509T/T and −800G/A TGF-β respectively and BC risk among a sub population of Iranian patients [142].

Kinases and growth factors

The human epidermal growth factor 2 (HER-2) is a transmembrane tyrosine kinase receptor which is involved in cell proliferation. It was shown that fourteen out of 60 (23%) had HER-2 overexpression in a subpopulation of malignant BC patients in central Iran [143]. There was also an inverse correlation between HER-2 expression and ER/PR levels in a group of Iranian BC cases [144]. Another study on BC patients in Kermanshah province of Iran have shown a significant association between age, stage, and HER2-neu expression. Therefore, they introduced the HER2-neu as an efficient prognostic and diagnostic marker in that population [145]. ErbB4 is a tyrosine kinase receptor belonging to the EGFR subfamily. Frequency of rs11895168 variant was analyzed in a subpopulation of central Iranian BC patients, and observed that none of the normal cases harbored the rs11895168 C allele. They introduced a significant correlation between C allele and higher risk of breast cancer, which can be related to the miR-1276 binding changes [146]. Another study has shown that there was a significant correlation between rs13423759 allele C of ERBB4 and increased risk of BC which can be associated with role of this allele in strengthening the miR-548as-3p/ErbB4 interaction. The rs13423759 allele A is also significantly associated with decreased risk of breast cancer. Therefore, they highlighted the role of rs13423759 as an efficient diagnostic biomarker among a group of Iranian BC patients [147]. The rs1836724 polymorphism of ErbB4 was correlated with risk of BC, in which the T allele carriers had decreased expression of ErbB4 and higher susceptibility for BC among a group of Iranian patients [148]. NGX6 has an epidermal growth factor (EGF)-like domain which functions as a negative growth factor through apoptosis induction and cell proliferation arrest [149, 150]. NGX6 exerts its negative role on cell cycle via down regulation of cyclin D1, A, and E [151]. It has been shown that the levels of NGX6 mRNA expression in Iranian BC tumors were significantly lower than that in the normal samples [152]. Neuropilin-1 (NRP1) as a receptor for VEGF and PlGF in endothelial cells plays key roles in cell survival, angiogenesis, and EMT [153]. It has been shown that there was significant correlation between NRP1 expression and lymph node involvement in which the patients with metastatic lymph nodes had higher levels of NRP1 expression in comparison with the lymph node-negative cases. Moreover, the tumors with higher stages and grades had higher levels of NRP1 expressions. Therefore, they introduced NRP1 as a metastatic diagnostic marker among a sub population of Iranian BC patients [154]. Insulin-like growth factor 1 (IGF-1) is one of the activators of the AKT pathway, which is a cell proliferation inducer and cell death suppressor. There is a polymorphic cytosine–adenine (CA) repeat located in 1 kb upstream of the IGF-1 start site which is associated with cancer [155]. Length of this dinucleotide repeat was assessed in a group of Iranian BC patients. They showed that the patients harboring an allele longer than 19 and shorted than 20 have higher and lower risks of breast cancer, respectively. Therefore, there was a correlation between BC and length of the IGF-1 CA repeat which seems related to the ethnicity [156]. Phosphatidylinositol-3 kinase (PI3K) is a heterodimeric protein comprising of regulatory and catalytic subunits encoded by PIK3R1 and PIK3CA respectively, which is involved in apoptosis and cell proliferation [157]. Mutational analysis of PIK3CA catalytic subunit was done in a group of Iranian BC patients, and showed 45% of 80 cases had mutated PIK3CA that was higher than the recent reports. Majority of mutations were observed in three hotspots belonging to exon 9 and 20. There was a significant correlation between PIK3CA mutation and low grade tumors [158]. KRAS oncogene is a member of the small GTPase superfamily, which is also associated with PI3-kinase signaling pathway. It has been reported that the rs61764370 and rs712 polymorphisms in KRAS increased and decreases the BC risk in a sub population of Iranian patients [159]. SPHK1 catalyzes the phosphorylation of sphingosine to sphingosine-1-phosphate (S1P), which is a ligand of G protein-coupled receptors and regulates cell proliferation. SPHK1 exerts its inflammatory and anti apoptotic roles through several signaling pathways such as TNF-alpha and NF-kappa-B. It has been observed that there was a positive correlation between SPHK1 expression in ER/PR negative tumors compared with positive BC cases. Moreover, there was an association between BMI and SPHK1 expression among the Iranian ER negative BC patients [160]. The Class I PI3K family phosphorylates PIP2 to PIP3 which subsequently activates AKT as a regulator of cell proliferation, adhesion, and migration [161]. PIK3CA is the catalytic subunit of class I PI3Ks [162] that is deregulated in various cancers [163]. A highly polymorphic intronic GT dinucleotide repeat in PIK3CA had direct correlation with risk of BC in a group of Iranian patients, in which the harbors of short allele (17 repeats) and long allele (more than 16 repeats) had significantly higher and lower risk of BC progression, respectively [164]. OCC1 is involved in differentiation of adipocytes. APPL2 is one of the small GTPase RAB5A/Rab5 effectors, which are associated with endosomal membranes and can interact with the NuRD/MeCP1 complex which is required for cell proliferation. Levels of OCC1 and APPL2 expression were assessed in BC tissues, and showed significant under and over expressions of APPL2 and OCC1 in tumors compared with corresponding normal margins, respectively. Therefore, they suggested that the OCC-1D variant suppresses the APPL2 and probably regulate the cell cycle through PI3K/AKT signaling pathway [165]. RIP1K and RIP3K are belonged to RIPK family and involved in inflammation and cell death, in response to tissue damage. It has been observed that the benign and malignant tumors had increased levels of RIP1K compared with normal tissues. Whereas the malignant tumors had decreased levels of RIP3K expression compared with normal and benign samples. Moreover the RIP1K and RIP3K had decreased and increased expressions among old Iranian BC patients with malignant tumors, respectively. The tumors with higher grade and larger size had increased levels of RIP1K expression. Whereas the RIP3K had decreased expression in malignant tumors with grade III [166].

Intracellular defense systems and drug resistance

Ubiquitin proteasome machinery is one of the main intracellular defence systems which is involved in degradation of aberrant and defective proteins. Moreover, it regulates the stability of cell cycle regulators. Ubiquitin–proteasome pathway involves several members such as Ubiquitin-activating (E1) and conjugating (E2) enzymes (E1) and ubiquitin ligases (E3). Since the lifetime regulation of cellular regulatory proteins including cell cycle and transcription factors is governed by the ubiquitin process, ubiquitine proteasome deregulation can be resulted in tumor progression [167]. UBE2Q2 expression was assessed in Iranian BC cases, and showed that the majority of tumor tissues had UBE2Q2 over expression compared with their corresponding normal margins. They introduced UBE2Q2 as a novel diagnostic marker among the Iranian BC patients [168]. Glutathione S-transferases (GSTs) as the cytoprotective factors detoxifie the carcinogens and chemotherapeutic drugs through the glutathione binding. Therefore, the human polymorphisms affects the individual ability to respond toward drugs and stresses. Although, the GSTM1 is expressed in a wide spectrum of tissues such as liver, stomach, and breast, GSTT1 enzyme is mainly observed in liver and erythrocytes [169]. The association between GSTM1, GSTT1 and GSTP1 genotypes and BC were assessed in a subpopulation of Iranian cases. It was reported that the GSTM1 null and GSTP1 Ile105Val genotypes were significantly correlated with the increased risk of BC. It seems that the cases with GSTM1 null, GSTT1 null, or GSTP1 Ile105Val Genotypes have low GST detoxification capacity, which can be resulted in higher accumulation of toxic compounds in such cases [170]. GSTO1 A140D and GSTO2 N142D polymorphisms were also associated with high risk of BC in a sub population of Iranian patients [171]. Cytochrome 450 (CYP450) is involved in oxidative catalysis of anticancer drugs and hormone synthesis. Therefore, assessment of CYP450 polymorphisms is required in anticancer therapy outcomes. CYP1A1 is involved in metabolism of xenobiotics and reactive epoxide production from aromatic compounds and steroid hormones [172]. It has been reported that the heterozygote carriers of 2455G (462Val) of CYP1A1 had significantly higher risk of BC in comparison with other genotypes. Moreover, heterozygote variant was more frequent in pre-menopausal patients, highlighting the role of this variation in early onset of BC among a group of Iranian patients in Eastern Azerbaijan [173]. Non functional CYP2D6*4 and 10 alleles were also frequent among BC patients in Northern Iran [174]. Tamoxifen is treatment option of ER-positive BC in premenopausal women [175, 176]. However, some patients do not response to the tamoxifen and die from tumor recurrence [177]. Tamoxifen is metabolized by cytochrome P450 2D6 (CYP2D6) in endoplasmic reticulum [178]. It has been shown that the HER2-neu positive Tamoxifen treated patients with CYP2D6 polymorphism had lower risk of tumor relapse in a sub population of Iranian BC patients [179]. Heat shock proteins (HSPs) are induced in response to anti-cancer drugs to maintain the cells in lethal conditions. Their cytoprotective function involve the correction of misfolded proteins and anti-apoptotic functions. Hsp27 regulates ability of cells to respond to the heat shock and oxidative stresses [180, 181]. Moreover, Hsp27 has an anti-apoptotic function through suppression of caspase-dependent apoptosis [182, 183]. It has been observed that there was a significant higher levels of serum anti- Hsp27 antibodies in BC compared with healthy Iranian cases [184]. The ATP-binding cassette (ABC) family regulates the drugs passage across cell membranes, which alters the kinetics of drugs. The ABCG2 is related with drug resistance in tumor cells and xenobiotic detoxification [185, 186]. It has been shown that there was a significant association between A allele of ABCG2 C421A variant and response to the Anthracyclines and Paclitaxol, and also increased BC risk in a group of Iranian BC patients [187].

Cell adhesion, cytoskeletal factors, and ECM

Alterations in adhesion properties facilitate the tumor cell detachment from the primary tumor bulk and formation of secondary tumors in distant organs. The CEACAM subfamily are belonged to the CEA family which are involved in cell adhesion, differentiation, apoptosis, and angiogenesis [188]. Levels of CEACAM19 expression was evaluated among a group of Iranian BC patients, showing a higher levels of CEACAM19 mRNA expression in tumors compared with normal tissues [189]. The MUC1 is a mucin glycoproteins expressing on the apical surface of epithelial breast cells and is involved in cell adhesion [190]. CA15-3 serum assay determines the MUC1 protein. CEA is one of the members of immunoglobulin family and is associated with tumors [191]. Serum levels of CEA and CA15-3 were assessed in BC compared with healthy controls among Iranian cases and showed a significant increase of CA15-3 and CEA in BC in comparison with normal cases. There were significant correlations between CEA and grade of tumor, and also between CA15-3 and tumor size [192]. MUC1 overexpression was also correlated with BC progression and metastasis among Iranian cases [193]. CDH1 tumor suppressor is a cell–cell adhesion glycoprotein which is associated with cell differentiation and polarity [194, 195]. A significant correlation between CDH1 −160C/A polymorphism and BC susceptibility was reported among a group of Iranian Kurdish patients in which the A allele of CDH1 −160C/A variant was significantly associated with BC metastasis [196]. CD44 is involved normally in cell adhesion, migration, angiogenesis, and apoptosis [197]. The CD44 protein increases cell proliferation and migration in BC through an interaction with hyaluronan. It has been reported that there was a significant correlation between A > G intronic polymorphism and grade 3 of tumors in Iranian BC patients, which can be related to generation of a new SC35 binding site and modulation of splicing process. Low grade (1/2) tumors were also associated with AA genotypes [198]. Epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein associated with cell–cell adhesions and is involved in cell proliferation in different cancers [199]. EpCAM induces the Lef1 transcription factor through presenilin-2 to bind with promoter sequences of target genes such as c-myc and cyclin A/E genes [200]. C-myc protooncogene has important functions in various cellular processes such as cell cycle, angiogenesis, and apoptosis [201]. It has been observed that there was a significant correlation between EpCAM/c-myc over expression and grade III among a group of Iranian BC patients [202]. Matrix metalloproteinases are involved in ECM degradation to facilitate the cell migration and metastasis during the tumor progression. CD10 is a zinc-dependant metalloproteinase that is highly expressed in kidney and lung tissues and participates in ECM degradation [203]. Regulation of cell adhesion facilitates the tumor metastasis. Therefore, tumor cells regulate the cell adhesion through proteolytic enzymes or stimulation of fibroblasts to secrete such enzymes. It has been observed that there were inverse significant associations between stromal CD10 expression, larger tumor size, metastatic lymph nodes, and grade among Iranian BC patients [204]. Caveola are structural proteins in formation of caveola which are mainly expressed in endothelial, adipose, and smooth muscle cells [205]. CAV-1 is associated with tyrosine phosphorylation and observed in a wide spectrum of cells [206]. Role of several SNPs in CAV-1 was evaluated in BC progression among a group of Iranian patients, and showed that the cases harboring homozygous AA genotype in T29107A, G21985A, and G14713A polymorphisms have higher risk of BC progression compared with the normal cases. In contrast, the C521A homozygous variant had a protective role, and it had a significant correlation with BMI. Therefore, they introduced C521A, G14713A, G21985A, and T29107A as efficient diagnostic markers of BC progression among Iranian cases [207]. The SYCP3 is a structural component of the synaptonemal complex associated with recombination and meiotic chromosome segregation. There was a noticeable SYCP3 over expression in tumors compared with normal tissues. They introduced the SYCP3 as a CTA in BC which can be used as an early detection marker among Iranian BC patients [208]. Syndecan-1(SDC1) is an ECM receptor belonging to the heparan sulfate proteoglycan family. The extracellular domain binds to the heparan and chondroitin sulfate whereas the cytoplasmic domain is associated with cytoskeleton during the cell migration. It has been reported that there was elevated serum levels of SDC1 in BC in comparison with the healthy cases, which was also positively associated with size of BC tumors among Iranian patients [209].

Cell signaling and self renewal

AMP-activated protein kinase (AMPK) is a cellular energy sensor, which is activated with elevated AMP/ATP ratio to induces the ATP generation. AMPK also acts as a tumor suppressor through cell cycle regulation. AMPK activates p53, which induces G1/S cell cycle arrest in response to the lack of glucose. Moreover, AMPK blocks CDKs via phosphorylation of p27 [210]. Levels of cAMP and cGMP as the second messengers are regulated via cyclic nucleotide phosphodiesterases (PDEs) [211]. PDE5 and PDE9 regulate the cGMP, which activates various downstream targets such as PKGs and ion channels [212]. Significant PDE5 and PDE9 over expressions has been observed in malignant tumors compared with benign tumors and normal margins. Moreover, there were significant correlations between phosphodiesterase expression and stage, grade and lymph node metastasis. Furthermore, there was a converse correlation between levels of expressions and age of patients. They concluded that the Iranian BC patients with higher levels of phosphodiesterases may have higher risks of malignant tumors [213]. Cyclic guanosine monophosphate (cGMP) participates in various signaling pathways through Protein Kinase G (PKG). PKGI and PKGII are serine/threonine kinases mediating the effects of cGMP [214]. It has been reported that the BC tissues had lower levels of PKG expression in comparison with the normal samples, highlighting the PKG as a tumor suppressor in a group of Iranian cases [215]. Notch is one of the main signaling pathways involved in cell proliferation, migration, and self renewal [216]. This pathway is a cell to cell contact process which is activated via the ligand binding with a family of trans membrane receptors (NOTCH1-4). Ligand binding releases the intracellular domain of Notch (ICN) into the cytoplasm which eventually enters to the nucleus where it regulated the expression of NOTCH target genes [217]. Levels of NOTCH1 mRNA expression as one of the NOTCH receptors was assessed in BC patients and showed a significant increase in invasive ductal types compared with other histopathological types. They introduced the NOTCH1 as a prognostic marker of IDC among Iranian patients [218]. WNT pathway is also another important process to maintain a normal balance between cell differentiation and proliferation. It is initiated through the cell surface receptors resulting in activation of cytoplasmic b-catenin which activates the LEF/TCF/PYGO2 transcriptional complex [219]. The WISP1 is belonged to the CTGF family and involved in WNT pathway. It also functions as an anti apoptotic factor through up regulation of BCL-X and inhibition of the P53 mediated apoptosis following the DNA damage via AKT activation. It has been reported that the metastatic BC tissues had significantly reduced levels of WISP1 mRNA expression in comparison with the normal subjects. Moreover, WISP1 expression was correlated with age and tumor size [220].
Cancer stem cells (CSC) are a small subpopulation of cells with self renewal and chemo-radiotherapeutic resistance abilities [221]. Aldehyde dehydrogenase 1 (ALDH1) has been suggested as a marker of mammary stem cells and prognostic marker [222, 223]. Epithelial and stromal expression of ALDH1 was analysed to assess the probable correlation between ALDH1 and clinicopathological features of breast tumors in a group of Iranian patients. They observed a significant converse correlation between ALDH1 and BRCA1 expressions. Moreover there was a correlation between ALDH1 +/BRCA1 low expression phenotype and high grade tumours [224]. BC cases are routinely undergone the different treatments such as surgery, radiotherapy, and chemotherapy. Hormone therapy is also one of the treatment options for the BC cases, in which the tamoxifen targets the positive estrogen receptor tumors through apoptosis induction and ER signaling inhibition [225, 226]. However, it has been observed that a noticeable ratio of tamoxifen treated cases have tumor relapse [227]. PAX2 is one of the members of PAX family of transcription factors which are involved in embryonic development of different organs [228]. PAX2 protein expression was assessed in tamoxifen treated BC patients, and showed that there was a correlation between PAX2 over expression and better survival. Moreover, the tamoxifen responsive cases had significantly higher levels of PAX2 expression compared with tamoxifen resistant patients [229]. MYC is an oncogene involving in various cellular processes, such as cell proliferation and apoptosis [230]. NDRG family is one of the targets of MYC which has four members including NDRG1-4 [231]. NDRG3 has high levels of expression in various tissues including prostate, testis, brain, heart, and kidney [232]. It has been suggested that the NDRG3 has a tumor suppressor role in BC patients, in which the triple negative and advanced stage BC tumors had the lowest levels of NDRG3 expression. Moreover, there was an inverse correlation between NDRG3 expression and survival rate, in which the higher levels of NDRG3 expression resulted in better survival rates among the Iranian BC patients [233].

Vitamin D and steroids

Steroid hormones exert their regulatory role on transcription of target genes through binding with steroid receptors including estrogen receptor (ER) and progesterone receptor (PR). ERα has an important function in BC progression through cell growth and proliferation induction. It has been shown that there was an increased expression of ERα in the levels of mRNA and protein in a sub population of Iranian BC tissues in comparison with normal margins and it was associated with tumor size [234]. A mutational analysis has also shown that the presence of the ERα gene A908G mutation among a sub population of Iranian cases with invasive BC. Moreover, they observed a significant correlation between ER-α A908G mutation and familial BC [235]. P450 family is one the most important genes which are involved in steroid hormones metabolism. It has been observed that there was a significant association between rs10,046 polymorphism of CYP19 gene and BC among a group of Iranian patients [236]. TNF-α is involved in estrogen synthesis [237, 238] and down-regulation of ER [239]. Steroid hormone receptor is a prognostic factors to identify sensitive patients for hormone therapy, and also is associated with higher survival rates [240]. It has been shown that there was a significant correlation between TNFA −308 A/G polymorphism and levels of ER expression in a sub population of Iranian BC patients. Moreover, the cases harboring TNFA2 and TNFB2 alleles had lower risk of PR positive tumors in comparison with the TNFA1/A1 and TNFB1/B1 homozygous genotypes. They highlighted the correlation between immune and endocrine systems in BC progression, in which higher levels of TNF-α inhibits the PR expression [241]. TNFSF4 is also a glycoprotein belonged to the TNF family which is expressed on activated T cells and various antigen presenting cells such as dendritic cells and B cells [242244]. It has been shown that the rs3850641 G allele is significantly correlated with an increased risk of BC among Iranian cases [245]. The inverse relation between 25-hydroxyvitamin D serum levels and BC can be related to the apoptotic and antiproliferative roles of vitamin D [246]. VDR is a nu-clear receptor for the steroid hormones participating in regulation target genes which are involved in cell proliferation [247, 248]. VDR/RXR complex binds to the promoter sequences of target genes to regulate their expression [249]. The length of VDR poly(A) microsatellite was assessed in a sub population of Iranian BC cases, and showed a significant correlation between increased BC risk and VDR poly(A) L variant [250]. This region is associated with mRNA stability, which highlights the key role of poly(A) microsatellite in regulation of VDR mRNA expression. CYP27B1 is involved in conversion of 25–hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 which finally regulates the transcription of target genes through VDR/RXR complex [251, 252]. This complex regulates the cell growth, apoptosis, and inflammation [253]. Finally the vitamin D pathway is terminated via CYP24A1 [254]. It has been reported that the levels of CYP27B1 mRNA expression in normal was higher than that in the tumor samples. In contrast, the tumors had significantly elevated levels of CYP24A1 expression compared with normal tissues. The CYP24A1 and CYP27B1 were significantly correlated with age and stage, respectively [255]. Another groups have also shown that there was a significant correlation between VDR BsmI polymorphism and elevated BC risk [256, 257]. CYP17 is a steroid monooxygenase which is involved in synthesis of glucocorticoids and sex steroids [258, 259]. It has been shown that the CYP17 MspA1 Polymorphism is probably age specific and is associated with increased risk of early onset BC among Iranian subjects [260].

Cancer testis antigens

Cancer-testis antigens (CTA) are commonly expressed in testis and also with a lower ratio in ovarian germ cells [261]. Tumor cells also express antigens which are restricted to the germ cells. CTAs participate in EMT, self renewal, and tumor invasion [262]. AKAP as a group of CTAs has critical roles in sperm function which exerts their role through the protein kinase A (PKA). The levels of AKAP3 mRNA expression was assessed in tumor compared with normal margins of a sub population of Iranian BC cases, and showed a significant lower expressions in tumors compared with normal tissues. However, there was an inverse correlation between the levels of AKAP3 expressions and tumor sizes and stages, highlighting that as a probable inhibitor of proliferation [263]. WW-binding protein 2 (WBP2) as a CT antigen also regulates the expression of ERα/PR target genes through activation of ERα/PR expression in BC [264]. It has been demonstrated that the WBP2NL is probably associated with cell proliferation in embryonic stem cells and tumor cell lines [265]. WBP2NL over expression was also observed among the Iranian BC patients, highlighting that as a novel prognostic factor [266]. It has been reported that there was a significant correlation between MAGE-1 expression and lymph node involvement, and also between positive nuclear MAGE-1 expression and tumor size among Iranian BC patients [267]. Expressional analysis of TSGA10 CTA was performed in Iranian BC patients and showed its expression in 70% of patients while the only 12% of patients had immune response against TSGA10 [268]. ODF is involved in sperm tail maintenance and centrosome matrix [269] which facilitates the tumor cell proliferation. The RHOXF2 is associated with cell transformation [270] and cell to cell contacts [271]. The ODF4 and RHOXF2 cancer testis antigens had overexpression in tumors compared with normal marines in a sub population of Iranian BC patients [272].

Mitochondrial DNA

Mitochondria as the powerhouse in the cells are involved in redox homeostasis, innate immunity, and apoptosis. Aberrant cellular energetics is one of the most critical risk factors during the tumor progression. Mitochondrial DNA mutations and enzyme defects are the main dysfunctions which cause the cellular energetic problems [273, 274]. The mitochondrial genome encodes various factors of respiratory chain and mitochondrial non coding RNAs [275]. ND4 as one of the respiratory chain components in mitochondria complex I (initiation of electron transport chain) is involved in various cancers [276]. Through the mitochondrial respiratory chain, reactive oxygen species (ROS) are generated due to the electron transfer, therefore it is really important to maintain the production and degradation of ROS, since there is not any protective factor in mitochondrial genome [277]. Mutational analysis of ND4 in a sub population of Iranian BC patients showed that there was a correlation between ND4 alteration and BC [278]. The mtDNA alterations are associated with the increased oxidative stresses and apoptotic resistance [279, 280]. The ATPase6 is belonged to the complex V genes, and contributed to the preservation of mtDNA [281]. The high frequency of ATPase6 mitochondrial mutations were observed in BC patients and highlighted the importance of mitochondrial gene variants in BC progression through modulation of metabolism, and can be introduced as molecular biomarkers among Iranian BC cases [282].

Conclusions

For the first time in the current review we have summarized all of the recent significant genetic markers among Iranian BC patients. It seems that the non-coding RNAs, epigenetic modifications, and immune responses are the most common reported cell and molecular processes which are involved in tumor progression among Iranian BC patients. Moreover, we concluded that there were fifteen out of 117 reported genes which were assessed in higher numbers of BC patients and controls and they can be considered as the main high risk genes among Iranian BC patients (Table 2). Indeed, it is believed that the current review will be useful to pave the way of introducing a population based diagnostic panel markers for the early detection of BC among Iranians. Moreover, current review clarifies the molecular and genetic bases of BC progression in this population.
Table 2
The most reported and high risk genes among Iranian BC patients
Gene
Number of studies
Number of patients (total)
Number of controls (total)
CYP2D6
2
185
FOXP3
2
95
80
LEPTIN
2
303
271
TGFβ
2
210
210
HER2
3
509
15
ERBB4
3
490
486
CASP8
2
263
203
P53
2
467
203
PTEN
3
260
70
VDR
3
477
497
ATM
3
298
248
BRCA1
3
259
MTHFR
2
378
306
DNMT3
2
172
138
ERα
2
169
157

Acknowledgements

Not applicable
Not applicable.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Almasi Z, Rafiemanesh H, Salehiniya H. Epidemiology characteristics and trends of incidence and morphology of stomach cancer in Iran. Asian Pac J Cancer Prev. 2015;16(7):2757–61.PubMedCrossRef Almasi Z, Rafiemanesh H, Salehiniya H. Epidemiology characteristics and trends of incidence and morphology of stomach cancer in Iran. Asian Pac J Cancer Prev. 2015;16(7):2757–61.PubMedCrossRef
2.
Zurück zum Zitat Ghoncheh M, Momenimovahed Z, Salehiniya H. Epidemiology, incidence and mortality of breast cancer in Asia. Asian Pac J Cancer Prev. 2016;17(S3):47–52.PubMedCrossRef Ghoncheh M, Momenimovahed Z, Salehiniya H. Epidemiology, incidence and mortality of breast cancer in Asia. Asian Pac J Cancer Prev. 2016;17(S3):47–52.PubMedCrossRef
3.
Zurück zum Zitat Mousavi SM, et al. Breast cancer in Iran: an epidemiological review. Breast J. 2007;13(4):383–91.PubMedCrossRef Mousavi SM, et al. Breast cancer in Iran: an epidemiological review. Breast J. 2007;13(4):383–91.PubMedCrossRef
4.
Zurück zum Zitat Sharifian A, et al. Burden of Breast Cancer in Iranian Women is Increasing. Asian Pac J Cancer Prev. 2015;16(12):5049–52.PubMedCrossRef Sharifian A, et al. Burden of Breast Cancer in Iranian Women is Increasing. Asian Pac J Cancer Prev. 2015;16(12):5049–52.PubMedCrossRef
5.
Zurück zum Zitat Mahdavifar N, et al. Spatial analysis of breast cancer incidence in Iran. Asian Pac J Cancer Prev. 2016;17(S3):59–64.PubMedCrossRef Mahdavifar N, et al. Spatial analysis of breast cancer incidence in Iran. Asian Pac J Cancer Prev. 2016;17(S3):59–64.PubMedCrossRef
6.
Zurück zum Zitat Afsharfard A, et al. Trends in epidemiology, clinical and histopathological characteristics of breast cancer in Iran: results of a 17 year study. Asian Pac J Cancer Prev. 2013;14(11):6905–11.PubMedCrossRef Afsharfard A, et al. Trends in epidemiology, clinical and histopathological characteristics of breast cancer in Iran: results of a 17 year study. Asian Pac J Cancer Prev. 2013;14(11):6905–11.PubMedCrossRef
7.
Zurück zum Zitat Abdulrahman GO, Rahman GA. Epidemiology of breast cancer in Europe and Africa. J Cancer Epidemiol. 2012;2012:915610.PubMedCrossRef Abdulrahman GO, Rahman GA. Epidemiology of breast cancer in Europe and Africa. J Cancer Epidemiol. 2012;2012:915610.PubMedCrossRef
9.
Zurück zum Zitat Iqbal J, et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–73.PubMedCrossRef Iqbal J, et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–73.PubMedCrossRef
10.
Zurück zum Zitat Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10(7):705–13.PubMedCrossRef Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10(7):705–13.PubMedCrossRef
11.
Zurück zum Zitat Xu X, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 1999;22(1):37–43.PubMedCrossRef Xu X, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 1999;22(1):37–43.PubMedCrossRef
12.
Zurück zum Zitat Sidransky D, et al. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992;52(10):2984–6.PubMed Sidransky D, et al. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992;52(10):2984–6.PubMed
14.
15.
Zurück zum Zitat Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.PubMedCrossRef Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.PubMedCrossRef
16.
Zurück zum Zitat Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10(6):389–402.PubMedPubMedCentralCrossRef Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10(6):389–402.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Danesh H, et al. Association study of miR-100, miR-124-1, miR-218-2, miR-301b, miR-605, and miR-4293 polymorphisms and the risk of breast cancer in a sample of Iranian population. Gene. 2018;647:73–8.PubMedCrossRef Danesh H, et al. Association study of miR-100, miR-124-1, miR-218-2, miR-301b, miR-605, and miR-4293 polymorphisms and the risk of breast cancer in a sample of Iranian population. Gene. 2018;647:73–8.PubMedCrossRef
18.
Zurück zum Zitat Zhang Y, et al. Estrogen receptor alpha signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2. J Biol Chem. 2012;287(49):41514–22.PubMedPubMedCentralCrossRef Zhang Y, et al. Estrogen receptor alpha signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2. J Biol Chem. 2012;287(49):41514–22.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Heydari N, et al. Overexpression of serum MicroRNA-140-3p in premenopausal women with newly diagnosed breast cancer. Gene. 2018;655:25–9.PubMedCrossRef Heydari N, et al. Overexpression of serum MicroRNA-140-3p in premenopausal women with newly diagnosed breast cancer. Gene. 2018;655:25–9.PubMedCrossRef
20.
Zurück zum Zitat Parchami Barjui S, et al. Study of correlation between genetic variants in three microRNA genes (hsa-miR-146a, hsa-miR-502 binding site, hsa-miR-27a) and breast cancer risk. Curr Res Transl Med. 2017;65(4):141–7.PubMedCrossRef Parchami Barjui S, et al. Study of correlation between genetic variants in three microRNA genes (hsa-miR-146a, hsa-miR-502 binding site, hsa-miR-27a) and breast cancer risk. Curr Res Transl Med. 2017;65(4):141–7.PubMedCrossRef
21.
Zurück zum Zitat Omrani M, et al. Hsa-mir-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population. Biomark Med. 2014;8(2):259–67.PubMedCrossRef Omrani M, et al. Hsa-mir-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population. Biomark Med. 2014;8(2):259–67.PubMedCrossRef
22.
Zurück zum Zitat Landi D, et al. A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. DNA Cell Biol. 2008;27(1):35–43.PubMedCrossRef Landi D, et al. A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. DNA Cell Biol. 2008;27(1):35–43.PubMedCrossRef
23.
Zurück zum Zitat Hashemi M, et al. miR-608 rs4919510 C > G polymorphism decreased the risk of breast cancer in an Iranian subpopulation. Exp Oncol. 2016;38(1):57–9.PubMedCrossRef Hashemi M, et al. miR-608 rs4919510 C > G polymorphism decreased the risk of breast cancer in an Iranian subpopulation. Exp Oncol. 2016;38(1):57–9.PubMedCrossRef
24.
Zurück zum Zitat Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 2008;68(19):8164–72.PubMedCrossRef Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 2008;68(19):8164–72.PubMedCrossRef
25.
Zurück zum Zitat Qi L, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9:163.PubMedPubMedCentralCrossRef Qi L, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9:163.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Savad S, et al. Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran. Asian Pac J Cancer Prev. 2012;13(3):873–7.PubMedCrossRef Savad S, et al. Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran. Asian Pac J Cancer Prev. 2012;13(3):873–7.PubMedCrossRef
27.
Zurück zum Zitat Zenz T, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood. 2009;113(16):3801–8.PubMedCrossRef Zenz T, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood. 2009;113(16):3801–8.PubMedCrossRef
28.
Zurück zum Zitat Mansoori B, et al. Micro RNA 34a and Let-7a expression in human breast cancers is associated with apoptotic expression genes. Asian Pac J Cancer Prev. 2016;17(4):1887–90.PubMedCrossRef Mansoori B, et al. Micro RNA 34a and Let-7a expression in human breast cancers is associated with apoptotic expression genes. Asian Pac J Cancer Prev. 2016;17(4):1887–90.PubMedCrossRef
29.
Zurück zum Zitat Saberi A, et al. MiR-328 may be considered as an oncogene in human invasive breast carcinoma. Iran Red Crescent Med J. 2016;18(11):e42360.PubMedPubMedCentral Saberi A, et al. MiR-328 may be considered as an oncogene in human invasive breast carcinoma. Iran Red Crescent Med J. 2016;18(11):e42360.PubMedPubMedCentral
30.
Zurück zum Zitat Damavandi Z, et al. Aberrant expression of breast development-related microRNAs, miR-22, miR-132, and miR-212, breast tumor tissues. J Breast Cancer. 2016;19(2):148–55.PubMedPubMedCentralCrossRef Damavandi Z, et al. Aberrant expression of breast development-related microRNAs, miR-22, miR-132, and miR-212, breast tumor tissues. J Breast Cancer. 2016;19(2):148–55.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Ma XP, et al. Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies. PLoS ONE. 2013;8(11):e79584.PubMedPubMedCentralCrossRef Ma XP, et al. Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies. PLoS ONE. 2013;8(11):e79584.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Nejati-Azar A, Alivand MR. miRNA 196a2(rs11614913) & 146a(rs2910164) polymorphisms & breast cancer risk for women in an Iranian population. Per Med. 2018;15(4):279–89.PubMedCrossRef Nejati-Azar A, Alivand MR. miRNA 196a2(rs11614913) & 146a(rs2910164) polymorphisms & breast cancer risk for women in an Iranian population. Per Med. 2018;15(4):279–89.PubMedCrossRef
33.
Zurück zum Zitat Cai Y, He J, Zhang D. Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway. Onco Targets Ther. 2015;8:2657–64.PubMedPubMedCentral Cai Y, He J, Zhang D. Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway. Onco Targets Ther. 2015;8:2657–64.PubMedPubMedCentral
34.
Zurück zum Zitat Ling H, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013;23(9):1446–61.PubMedPubMedCentralCrossRef Ling H, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013;23(9):1446–61.PubMedPubMedCentralCrossRef
35.
36.
37.
Zurück zum Zitat Hassanzarei S, et al. Genetic polymorphisms of HOTAIR gene are associated with the risk of breast cancer in a sample of southeast Iranian population. Tumour Biol. 2017;39(10):1010428317727539.PubMedCrossRef Hassanzarei S, et al. Genetic polymorphisms of HOTAIR gene are associated with the risk of breast cancer in a sample of southeast Iranian population. Tumour Biol. 2017;39(10):1010428317727539.PubMedCrossRef
38.
Zurück zum Zitat Zhouravleva G, et al. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J. 1995;14(16):4065–72.PubMedPubMedCentralCrossRef Zhouravleva G, et al. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J. 1995;14(16):4065–72.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Hoshino S, et al. Novel function of the eukaryotic polypeptide-chain releasing factor 3 (eRF3/GSPT) in the mRNA degradation pathway. Biochemistry (Mosc). 1999;64(12):1367–72. Hoshino S, et al. Novel function of the eukaryotic polypeptide-chain releasing factor 3 (eRF3/GSPT) in the mRNA degradation pathway. Biochemistry (Mosc). 1999;64(12):1367–72.
40.
Zurück zum Zitat Hansen LL, Jakobsen CG, Justesen J. Assignment of the human peptide chain release factor 3 (GSPT2) to Xp11.23– > p11.21 and of the distal marker DXS1039 by radiation hybrid mapping. Cytogenet Cell Genet. 1999;86(3–4):250–1.PubMedCrossRef Hansen LL, Jakobsen CG, Justesen J. Assignment of the human peptide chain release factor 3 (GSPT2) to Xp11.23– > p11.21 and of the distal marker DXS1039 by radiation hybrid mapping. Cytogenet Cell Genet. 1999;86(3–4):250–1.PubMedCrossRef
41.
Zurück zum Zitat Ozawa K, et al. Mapping of the human GSPT1 gene, a human homolog of the yeast GST1 gene, to chromosomal band 16p131. Somat Cell Mol Genet. 1992;18(2):189–94.PubMedCrossRef Ozawa K, et al. Mapping of the human GSPT1 gene, a human homolog of the yeast GST1 gene, to chromosomal band 16p131. Somat Cell Mol Genet. 1992;18(2):189–94.PubMedCrossRef
42.
Zurück zum Zitat Miri M, et al. GGCn polymorphism of eRF3a/GSPT1 gene and breast cancer susceptibility. Med Oncol. 2012;29(3):1581–5.PubMedCrossRef Miri M, et al. GGCn polymorphism of eRF3a/GSPT1 gene and breast cancer susceptibility. Med Oncol. 2012;29(3):1581–5.PubMedCrossRef
43.
44.
Zurück zum Zitat Ueland PM, et al. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci. 2001;22(4):195–201.PubMedCrossRef Ueland PM, et al. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci. 2001;22(4):195–201.PubMedCrossRef
46.
Zurück zum Zitat Rezaei H, Rassi H, Mansur FN. Investigation of Methylenetetrahydrofolate reductase C677T polymorphism and human papilloma virus genotypes in Iranian breast cancer. Monoclon Antib Immunodiagn Immunother. 2017;36(3):124–8.PubMedCrossRef Rezaei H, Rassi H, Mansur FN. Investigation of Methylenetetrahydrofolate reductase C677T polymorphism and human papilloma virus genotypes in Iranian breast cancer. Monoclon Antib Immunodiagn Immunother. 2017;36(3):124–8.PubMedCrossRef
47.
Zurück zum Zitat Johansson HJ, et al. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun. 2013;4:2175.PubMedCrossRef Johansson HJ, et al. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun. 2013;4:2175.PubMedCrossRef
48.
Zurück zum Zitat Jahangiri R, et al. Expression and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in tamoxifen-treated breast cancer patients. Gene. 2018;685:24–31.PubMedCrossRef Jahangiri R, et al. Expression and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in tamoxifen-treated breast cancer patients. Gene. 2018;685:24–31.PubMedCrossRef
49.
Zurück zum Zitat Eftekhar E, et al. The study of DNA methyltransferase-3B promoter variant genotype among iranian sporadic breast cancer patients. Iran J Med Sci. 2014;39(3):268–74.PubMedPubMedCentral Eftekhar E, et al. The study of DNA methyltransferase-3B promoter variant genotype among iranian sporadic breast cancer patients. Iran J Med Sci. 2014;39(3):268–74.PubMedPubMedCentral
50.
Zurück zum Zitat Ghavami S, et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet. 2009;46(8):497–510.PubMedCrossRef Ghavami S, et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet. 2009;46(8):497–510.PubMedCrossRef
51.
Zurück zum Zitat Hashemi M, et al. Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8 -652 6 N ins/del promoter polymorphism (rs3834129) in breast cancer. Gene. 2012;505(1):176–9.PubMedCrossRef Hashemi M, et al. Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8 -652 6 N ins/del promoter polymorphism (rs3834129) in breast cancer. Gene. 2012;505(1):176–9.PubMedCrossRef
52.
Zurück zum Zitat Aghababazadeh M, et al. Downregulation of Caspase 8 in a group of Iranian breast cancer patients—a pilot study. J Egypt Natl Canc Inst. 2017;29(4):191–5.PubMedCrossRef Aghababazadeh M, et al. Downregulation of Caspase 8 in a group of Iranian breast cancer patients—a pilot study. J Egypt Natl Canc Inst. 2017;29(4):191–5.PubMedCrossRef
53.
Zurück zum Zitat Parant JM, Lozano G. Disrupting TP53 in mouse models of human cancers. Hum Mutat. 2003;21(3):321–6.PubMedCrossRef Parant JM, Lozano G. Disrupting TP53 in mouse models of human cancers. Hum Mutat. 2003;21(3):321–6.PubMedCrossRef
54.
Zurück zum Zitat Eskandari-Nasab E, et al. Effect of TP53 16-bp and beta-TrCP 9-bp INS/DEL polymorphisms in relation to risk of breast cancer. Gene. 2015;568(2):181–5.PubMedCrossRef Eskandari-Nasab E, et al. Effect of TP53 16-bp and beta-TrCP 9-bp INS/DEL polymorphisms in relation to risk of breast cancer. Gene. 2015;568(2):181–5.PubMedCrossRef
55.
Zurück zum Zitat Payandeh M, et al. Expression of p53 breast cancer in kurdish women in the West of Iran: a reverse correlation with lymph node metastasis. Asian Pac J Cancer Prev. 2016;17(3):1261–4.PubMedCrossRef Payandeh M, et al. Expression of p53 breast cancer in kurdish women in the West of Iran: a reverse correlation with lymph node metastasis. Asian Pac J Cancer Prev. 2016;17(3):1261–4.PubMedCrossRef
58.
Zurück zum Zitat Rostamizadeh L, et al. Bcl-2 gene expression in human breast cancers in iran. Asian Pac J Cancer Prev. 2013;14(7):4209–14.PubMedCrossRef Rostamizadeh L, et al. Bcl-2 gene expression in human breast cancers in iran. Asian Pac J Cancer Prev. 2013;14(7):4209–14.PubMedCrossRef
59.
Zurück zum Zitat Freeman DJ, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003;3(2):117–30.PubMedCrossRef Freeman DJ, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003;3(2):117–30.PubMedCrossRef
60.
Zurück zum Zitat Li AG, et al. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23(4):575–87.PubMedCrossRef Li AG, et al. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23(4):575–87.PubMedCrossRef
61.
Zurück zum Zitat Golmohammadi R, et al. Prognostic role of PTEN gene expression in breast cancer patients from north-east Iran. Asian Pac J Cancer Prev. 2016;17(9):4527–31.PubMed Golmohammadi R, et al. Prognostic role of PTEN gene expression in breast cancer patients from north-east Iran. Asian Pac J Cancer Prev. 2016;17(9):4527–31.PubMed
62.
Zurück zum Zitat Sadeq V, Isar N, Manoochehr T. Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation. Med Oncol. 2011;28(2):420–3.PubMedCrossRef Sadeq V, Isar N, Manoochehr T. Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation. Med Oncol. 2011;28(2):420–3.PubMedCrossRef
63.
Zurück zum Zitat Yari K, Payandeh M, Rahimi Z. Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran. Tumour Biol. 2016;37(6):8145–52.PubMedCrossRef Yari K, Payandeh M, Rahimi Z. Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran. Tumour Biol. 2016;37(6):8145–52.PubMedCrossRef
64.
Zurück zum Zitat Ghaffari K, et al. BIRC5 genomic copy number variation in early-onset breast cancer. Iran Biomed J. 2016;20(4):241–5.PubMedPubMedCentral Ghaffari K, et al. BIRC5 genomic copy number variation in early-onset breast cancer. Iran Biomed J. 2016;20(4):241–5.PubMedPubMedCentral
65.
Zurück zum Zitat Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264(1):42–55.PubMedCrossRef Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264(1):42–55.PubMedCrossRef
66.
Zurück zum Zitat Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704–7.CrossRefPubMed Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704–7.CrossRefPubMed
67.
Zurück zum Zitat Nielsen NH, et al. Methylation of the p16(Ink4a) tumor suppressor gene 5′-CpG island in breast cancer. Cancer Lett. 2001;163(1):59–69.PubMedCrossRef Nielsen NH, et al. Methylation of the p16(Ink4a) tumor suppressor gene 5′-CpG island in breast cancer. Cancer Lett. 2001;163(1):59–69.PubMedCrossRef
68.
Zurück zum Zitat Kannan K, et al. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci USA. 2003;100(3):1221–5.PubMedCrossRefPubMedCentral Kannan K, et al. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci USA. 2003;100(3):1221–5.PubMedCrossRefPubMedCentral
69.
Zurück zum Zitat Malumbres M, et al. Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol Cell Biol. 2000;20(8):2915–25.PubMedPubMedCentralCrossRef Malumbres M, et al. Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol Cell Biol. 2000;20(8):2915–25.PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat Vallian S, et al. Methylation status of p16 INK4A tumor suppressor gene in Iranian patients with sporadic breast cancer. J Cancer Res Clin Oncol. 2009;135(8):991–6.PubMedCrossRef Vallian S, et al. Methylation status of p16 INK4A tumor suppressor gene in Iranian patients with sporadic breast cancer. J Cancer Res Clin Oncol. 2009;135(8):991–6.PubMedCrossRef
71.
Zurück zum Zitat Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst. 2000;92(10):795–802.PubMedCrossRef Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst. 2000;92(10):795–802.PubMedCrossRef
72.
Zurück zum Zitat Salimi M, Mozdarani H, Majidzadeh K. Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients. Med Oncol. 2012;29(3):1502–9.PubMedCrossRef Salimi M, Mozdarani H, Majidzadeh K. Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients. Med Oncol. 2012;29(3):1502–9.PubMedCrossRef
73.
Zurück zum Zitat Mehdipour P, et al. Importance of ATM gene as a susceptible trait: predisposition role of D1853 N polymorphism in breast cancer. Med Oncol. 2011;28(3):733–7.PubMedCrossRef Mehdipour P, et al. Importance of ATM gene as a susceptible trait: predisposition role of D1853 N polymorphism in breast cancer. Med Oncol. 2011;28(3):733–7.PubMedCrossRef
74.
Zurück zum Zitat Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature. 1999;401(6750):297–300.PubMedCrossRef Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature. 1999;401(6750):297–300.PubMedCrossRef
75.
Zurück zum Zitat Amininia S, et al. Association between CCNE1 polymorphisms and the risk of breast cancer in a sample of southeast Iranian population. Med Oncol. 2014;31(10):189.PubMedCrossRef Amininia S, et al. Association between CCNE1 polymorphisms and the risk of breast cancer in a sample of southeast Iranian population. Med Oncol. 2014;31(10):189.PubMedCrossRef
76.
Zurück zum Zitat Yoshihara T, Collado D, Hamaguchi M. Cyclin D1 down-regulation is essential for DBC2′s tumor suppressor function. Biochem Biophys Res Commun. 2007;358(4):1076–9.PubMedPubMedCentralCrossRef Yoshihara T, Collado D, Hamaguchi M. Cyclin D1 down-regulation is essential for DBC2′s tumor suppressor function. Biochem Biophys Res Commun. 2007;358(4):1076–9.PubMedPubMedCentralCrossRef
77.
Zurück zum Zitat Siripurapu V, et al. DBC2 significantly influences cell-cycle, apoptosis, cytoskeleton and membrane-trafficking pathways. J Mol Biol. 2005;346(1):83–9.PubMedCrossRef Siripurapu V, et al. DBC2 significantly influences cell-cycle, apoptosis, cytoskeleton and membrane-trafficking pathways. J Mol Biol. 2005;346(1):83–9.PubMedCrossRef
78.
Zurück zum Zitat Hajikhan Mirzaei M, et al. Evaluation of Methylation Status in the 5′UTR Promoter Region of the DBC2 Gene as a Biomarker in Sporadic Breast Cancer. Cell J. 2012;14(1):19–24.PubMedPubMedCentral Hajikhan Mirzaei M, et al. Evaluation of Methylation Status in the 5′UTR Promoter Region of the DBC2 Gene as a Biomarker in Sporadic Breast Cancer. Cell J. 2012;14(1):19–24.PubMedPubMedCentral
79.
Zurück zum Zitat Golmohammadi R, et al. A single nucleotide polymorphism in codon F31I and V57I of the AURKA gene in invasive ductal breast carcinoma in Middle East. Medicine (Baltimore). 2017;96(37):e7933.CrossRef Golmohammadi R, et al. A single nucleotide polymorphism in codon F31I and V57I of the AURKA gene in invasive ductal breast carcinoma in Middle East. Medicine (Baltimore). 2017;96(37):e7933.CrossRef
81.
Zurück zum Zitat Dai L, et al. XRCC1 gene polymorphisms and esophageal squamous cell carcinoma risk in Chinese population: a meta-analysis of case–control studies. Int J Cancer. 2009;125(5):1102–9.PubMedCrossRef Dai L, et al. XRCC1 gene polymorphisms and esophageal squamous cell carcinoma risk in Chinese population: a meta-analysis of case–control studies. Int J Cancer. 2009;125(5):1102–9.PubMedCrossRef
82.
Zurück zum Zitat Yu H, et al. Interaction between XRCC1 polymorphisms and intake of long-term stored rice in the risk of esophageal squamous cell carcinoma: a case-control study. Biomed Environ Sci. 2011;24(3):268–74.PubMed Yu H, et al. Interaction between XRCC1 polymorphisms and intake of long-term stored rice in the risk of esophageal squamous cell carcinoma: a case-control study. Biomed Environ Sci. 2011;24(3):268–74.PubMed
83.
Zurück zum Zitat Jalali C, et al. Association of XRCC1 Trp194 allele with risk of breast cancer, and Ki67 protein status in breast tumor tissues. Saudi Med J. 2016;37(6):624–30.PubMedPubMedCentralCrossRef Jalali C, et al. Association of XRCC1 Trp194 allele with risk of breast cancer, and Ki67 protein status in breast tumor tissues. Saudi Med J. 2016;37(6):624–30.PubMedPubMedCentralCrossRef
84.
Zurück zum Zitat Liu L, et al. Functional FEN1 genetic variants contribute to risk of hepatocellular carcinoma, esophageal cancer, gastric cancer and colorectal cancer. Carcinogenesis. 2012;33(1):119–23.PubMedCrossRef Liu L, et al. Functional FEN1 genetic variants contribute to risk of hepatocellular carcinoma, esophageal cancer, gastric cancer and colorectal cancer. Carcinogenesis. 2012;33(1):119–23.PubMedCrossRef
85.
Zurück zum Zitat Shen B, et al. Multiple but dissectible functions of FEN-1 nucleases in nucleic acid processing, genome stability and diseases. BioEssays. 2005;27(7):717–29.PubMedCrossRef Shen B, et al. Multiple but dissectible functions of FEN-1 nucleases in nucleic acid processing, genome stability and diseases. BioEssays. 2005;27(7):717–29.PubMedCrossRef
87.
Zurück zum Zitat Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171–82.PubMedCrossRef Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171–82.PubMedCrossRef
88.
Zurück zum Zitat Madjd Z, et al. Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas. Asian Pac J Cancer Prev. 2014;15(4):1783–9.PubMedCrossRef Madjd Z, et al. Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas. Asian Pac J Cancer Prev. 2014;15(4):1783–9.PubMedCrossRef
89.
Zurück zum Zitat Gatei M, et al. Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res. 2000;60(12):3299–304.PubMed Gatei M, et al. Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res. 2000;60(12):3299–304.PubMed
90.
Zurück zum Zitat Moynahan ME, et al. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;4(4):511–8.PubMedCrossRef Moynahan ME, et al. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;4(4):511–8.PubMedCrossRef
91.
Zurück zum Zitat Hallajian Z, Mahjoubi F, Nafissi N. Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients. Breast Cancer. 2017;24(4):624–34.PubMedCrossRef Hallajian Z, Mahjoubi F, Nafissi N. Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients. Breast Cancer. 2017;24(4):624–34.PubMedCrossRef
92.
93.
Zurück zum Zitat Paterson JW. BRCA1: a review of structure and putative functions. Dis Markers. 1998;13(4):261–74.PubMedCrossRef Paterson JW. BRCA1: a review of structure and putative functions. Dis Markers. 1998;13(4):261–74.PubMedCrossRef
94.
Zurück zum Zitat Darbeheshti F, et al. Comparison of BRCA1 expression between triple-negative and luminal breast tumors. Iran Biomed J. 2018;22(3):210–4.PubMedPubMedCentral Darbeheshti F, et al. Comparison of BRCA1 expression between triple-negative and luminal breast tumors. Iran Biomed J. 2018;22(3):210–4.PubMedPubMedCentral
95.
Zurück zum Zitat Madjd Z, et al. BRCA1 protein expression level and CD44(+)phenotype in breast cancer patients. Cell J. 2011;13(3):155–62.PubMedPubMedCentral Madjd Z, et al. BRCA1 protein expression level and CD44(+)phenotype in breast cancer patients. Cell J. 2011;13(3):155–62.PubMedPubMedCentral
96.
Zurück zum Zitat Rezaei M, et al. APOBEC3 deletion is associated with breast cancer risk in a sample of southeast Iranian population. Int J Mol Cell Med. 2015;4(2):103–8.PubMedPubMedCentral Rezaei M, et al. APOBEC3 deletion is associated with breast cancer risk in a sample of southeast Iranian population. Int J Mol Cell Med. 2015;4(2):103–8.PubMedPubMedCentral
97.
Zurück zum Zitat Hussain S, et al. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum Mol Genet. 2003;12(19):2503–10.PubMedCrossRef Hussain S, et al. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum Mol Genet. 2003;12(19):2503–10.PubMedCrossRef
98.
Zurück zum Zitat Abbasi S, Rasouli M. A rare FANCA gene variation as a breast cancer susceptibility allele in an Iranian population. Mol Med Rep. 2017;15(6):3983–8.PubMedPubMedCentralCrossRef Abbasi S, Rasouli M. A rare FANCA gene variation as a breast cancer susceptibility allele in an Iranian population. Mol Med Rep. 2017;15(6):3983–8.PubMedPubMedCentralCrossRef
99.
100.
Zurück zum Zitat Vodenicharov MD, Wellinger RJ. The cell division cycle puts up with unprotected telomeres: cell cycle regulated telomere uncapping as a means to achieve telomere homeostasis. Cell Cycle. 2007;6(10):1161–7.PubMedCrossRef Vodenicharov MD, Wellinger RJ. The cell division cycle puts up with unprotected telomeres: cell cycle regulated telomere uncapping as a means to achieve telomere homeostasis. Cell Cycle. 2007;6(10):1161–7.PubMedCrossRef
102.
Zurück zum Zitat Hashemi M, et al. Association between hTERT polymorphisms and the risk of breast cancer in a sample of Southeast Iranian population. BMC Res Notes. 2014;7:895.PubMedPubMedCentralCrossRef Hashemi M, et al. Association between hTERT polymorphisms and the risk of breast cancer in a sample of Southeast Iranian population. BMC Res Notes. 2014;7:895.PubMedPubMedCentralCrossRef
104.
Zurück zum Zitat Elliott RL, et al. Human leukocyte antigen G expression in breast cancer: role in immunosuppression. Cancer Biother Radiopharm. 2011;26(2):153–7.PubMedCrossRef Elliott RL, et al. Human leukocyte antigen G expression in breast cancer: role in immunosuppression. Cancer Biother Radiopharm. 2011;26(2):153–7.PubMedCrossRef
105.
Zurück zum Zitat Pistillo MP, et al. Biochemical analysis of HLA class I subunits expression in breast cancer tissues. Hum Immunol. 2000;61(4):397–407.PubMedCrossRef Pistillo MP, et al. Biochemical analysis of HLA class I subunits expression in breast cancer tissues. Hum Immunol. 2000;61(4):397–407.PubMedCrossRef
106.
Zurück zum Zitat Salih HR, Nussler V. Commentary: immune escape versus tumor tolerance: how do tumors evade immune surveillance? Eur J Med Res. 2001;6(8):323–32.PubMed Salih HR, Nussler V. Commentary: immune escape versus tumor tolerance: how do tumors evade immune surveillance? Eur J Med Res. 2001;6(8):323–32.PubMed
107.
Zurück zum Zitat Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest. 2006;24(2):178–86.PubMedCrossRef Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest. 2006;24(2):178–86.PubMedCrossRef
108.
Zurück zum Zitat Haghi M, et al. 14-bp insertion/deletion polymorphism of the HLA-G gene in breast cancer among women from north western Iran. Asian Pac J Cancer Prev. 2015;16(14):6155–8.PubMedCrossRef Haghi M, et al. 14-bp insertion/deletion polymorphism of the HLA-G gene in breast cancer among women from north western Iran. Asian Pac J Cancer Prev. 2015;16(14):6155–8.PubMedCrossRef
109.
Zurück zum Zitat Mahmoodi M, et al. HLA-DRB1,-DQA1 and -DQB1 allele and haplotype frequencies in female patients with early onset breast cancer. Pathol Oncol Res. 2012;18(1):49–55.PubMedCrossRef Mahmoodi M, et al. HLA-DRB1,-DQA1 and -DQB1 allele and haplotype frequencies in female patients with early onset breast cancer. Pathol Oncol Res. 2012;18(1):49–55.PubMedCrossRef
110.
Zurück zum Zitat Ghaderi A, et al. HLA-DBR 1 alleles and the susceptibility of Iranian patients with breast cancer. Pathol Oncol Res. 2001;7(1):39–41.PubMedCrossRef Ghaderi A, et al. HLA-DBR 1 alleles and the susceptibility of Iranian patients with breast cancer. Pathol Oncol Res. 2001;7(1):39–41.PubMedCrossRef
111.
Zurück zum Zitat Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003;111(4):677–90 (quiz 691).PubMedCrossRef Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003;111(4):677–90 (quiz 691).PubMedCrossRef
113.
Zurück zum Zitat Faghih Z, et al. Interleukin13 haplotypes and susceptibility of Iranian women to breast cancer. Mol Biol Rep. 2009;36(7):1923–8.PubMedCrossRef Faghih Z, et al. Interleukin13 haplotypes and susceptibility of Iranian women to breast cancer. Mol Biol Rep. 2009;36(7):1923–8.PubMedCrossRef
114.
Zurück zum Zitat Owaki T, et al. A role for IL-27 in early regulation of Th1 differentiation. J Immunol. 2005;175(4):2191–200.PubMedCrossRef Owaki T, et al. A role for IL-27 in early regulation of Th1 differentiation. J Immunol. 2005;175(4):2191–200.PubMedCrossRef
115.
Zurück zum Zitat Pflanz S, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4 + T cells. Immunity. 2002;16(6):779–90.PubMedCrossRef Pflanz S, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4 + T cells. Immunity. 2002;16(6):779–90.PubMedCrossRef
116.
Zurück zum Zitat Oppmann B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–25.PubMedCrossRef Oppmann B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–25.PubMedCrossRef
117.
Zurück zum Zitat Aggarwal S, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3):1910–4.PubMedCrossRef Aggarwal S, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3):1910–4.PubMedCrossRef
118.
Zurück zum Zitat Zheng Y, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445(7128):648–51.PubMedCrossRef Zheng Y, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445(7128):648–51.PubMedCrossRef
119.
Zurück zum Zitat Khodadadi A, et al. IL-23/IL-27 Ratio in Peripheral Blood of Patients with Breast Cancer. Iran J Med Sci. 2014;39(4):350–6.PubMedPubMedCentral Khodadadi A, et al. IL-23/IL-27 Ratio in Peripheral Blood of Patients with Breast Cancer. Iran J Med Sci. 2014;39(4):350–6.PubMedPubMedCentral
120.
Zurück zum Zitat Vahedi L, et al. Investigation of CCR120 marker expression using immunohistochemical method and its association with clinicopathologic properties in patients with breast cancer. Int J Hematol Oncol Stem Cell Res. 2018;12(2):103–10.PubMedPubMedCentral Vahedi L, et al. Investigation of CCR120 marker expression using immunohistochemical method and its association with clinicopathologic properties in patients with breast cancer. Int J Hematol Oncol Stem Cell Res. 2018;12(2):103–10.PubMedPubMedCentral
121.
Zurück zum Zitat Yamashita U, Kuroda E. Regulation of macrophage-derived chemokine (MDC, CCL22) production. Crit Rev Immunol. 2002;22(2):105–14.PubMedCrossRef Yamashita U, Kuroda E. Regulation of macrophage-derived chemokine (MDC, CCL22) production. Crit Rev Immunol. 2002;22(2):105–14.PubMedCrossRef
122.
Zurück zum Zitat Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127(4):759–67.PubMed Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127(4):759–67.PubMed
123.
Zurück zum Zitat Jafarzadeh A, et al. Higher circulating levels of chemokine CCL22 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism. Tumour Biol. 2015;36(2):1163–71.PubMedCrossRef Jafarzadeh A, et al. Higher circulating levels of chemokine CCL22 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism. Tumour Biol. 2015;36(2):1163–71.PubMedCrossRef
124.
Zurück zum Zitat Dayer R, et al. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma: a potent biomarker predicting lymph node metastasis. J Cancer Res Ther. 2018;14(2):345–50.PubMed Dayer R, et al. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma: a potent biomarker predicting lymph node metastasis. J Cancer Res Ther. 2018;14(2):345–50.PubMed
125.
Zurück zum Zitat Fontenot JD, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22(3):329–41.PubMedCrossRef Fontenot JD, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22(3):329–41.PubMedCrossRef
126.
Zurück zum Zitat Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–61.PubMedCrossRef Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–61.PubMedCrossRef
127.
Zurück zum Zitat Jaberipour M, et al. Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res. 2010;16(4):547–51.PubMedCrossRef Jaberipour M, et al. Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res. 2010;16(4):547–51.PubMedCrossRef
128.
Zurück zum Zitat Hamidinia M, et al. Concomitant Increase of OX40 and FOXP3 transcripts in peripheral blood of patients with breast cancer. Iran J Immunol. 2013;10(1):22–30.PubMed Hamidinia M, et al. Concomitant Increase of OX40 and FOXP3 transcripts in peripheral blood of patients with breast cancer. Iran J Immunol. 2013;10(1):22–30.PubMed
129.
Zurück zum Zitat Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627–35.PubMedCrossRef Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627–35.PubMedCrossRef
130.
Zurück zum Zitat Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and inflammation: new insights into breast cancer development and progression. Am Soc Clin Oncol Educ Book. 2013;1:46–51.CrossRef Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and inflammation: new insights into breast cancer development and progression. Am Soc Clin Oncol Educ Book. 2013;1:46–51.CrossRef
131.
Zurück zum Zitat Pierce BL, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(21):3437–44.PubMedPubMedCentralCrossRef Pierce BL, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(21):3437–44.PubMedPubMedCentralCrossRef
132.
Zurück zum Zitat Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007;14(2):189–206.PubMedCrossRef Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007;14(2):189–206.PubMedCrossRef
133.
Zurück zum Zitat Guo S, et al. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta. 2012;1825(2):207–22.PubMedPubMedCentral Guo S, et al. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta. 2012;1825(2):207–22.PubMedPubMedCentral
134.
Zurück zum Zitat Rostami S, Kohan L, Mohammadianpanah M. The LEP G-2548A gene polymorphism is associated with age at menarche and breast cancer susceptibility. Gene. 2015;557(2):154–7.PubMedCrossRef Rostami S, Kohan L, Mohammadianpanah M. The LEP G-2548A gene polymorphism is associated with age at menarche and breast cancer susceptibility. Gene. 2015;557(2):154–7.PubMedCrossRef
135.
Zurück zum Zitat Babaei Z, et al. Relationship of obesity with serum concentrations of leptin, CRP and IL-6 in breast cancer survivors. J Egypt Natl Canc Inst. 2015;27(4):223–9.PubMedCrossRef Babaei Z, et al. Relationship of obesity with serum concentrations of leptin, CRP and IL-6 in breast cancer survivors. J Egypt Natl Canc Inst. 2015;27(4):223–9.PubMedCrossRef
136.
Zurück zum Zitat Mohammadzadeh G, et al. The relationship between -2548 G/A Leptin gene polymorphism and risk of breast cancer and serum leptin levels in Ahvazian women. Iran J Cancer Prev. 2015;8(2):100–8.PubMedPubMedCentral Mohammadzadeh G, et al. The relationship between -2548 G/A Leptin gene polymorphism and risk of breast cancer and serum leptin levels in Ahvazian women. Iran J Cancer Prev. 2015;8(2):100–8.PubMedPubMedCentral
137.
Zurück zum Zitat Basu B, et al. D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in jurkat T leukemic cells. J Biol Chem. 2010;285(35):27026–32.PubMedPubMedCentralCrossRef Basu B, et al. D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in jurkat T leukemic cells. J Biol Chem. 2010;285(35):27026–32.PubMedPubMedCentralCrossRef
138.
Zurück zum Zitat Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182–217.PubMedCrossRef Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182–217.PubMedCrossRef
139.
Zurück zum Zitat Kirillova GP, et al. Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays. J Neurosci Methods. 2008;174(2):272–80.PubMedPubMedCentralCrossRef Kirillova GP, et al. Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays. J Neurosci Methods. 2008;174(2):272–80.PubMedPubMedCentralCrossRef
140.
Zurück zum Zitat Pornour M, et al. Dopamine receptor gene (DRD1-DRD5) expression changes as stress factors associated with breast cancer. Asian Pac J Cancer Prev. 2014;15(23):10339–43.PubMedCrossRef Pornour M, et al. Dopamine receptor gene (DRD1-DRD5) expression changes as stress factors associated with breast cancer. Asian Pac J Cancer Prev. 2014;15(23):10339–43.PubMedCrossRef
141.
Zurück zum Zitat Amani D, et al. Transforming growth factor beta1 (TGFbeta1) polymorphisms and breast cancer risk. Tumour Biol. 2014;35(5):4757–64.PubMedCrossRef Amani D, et al. Transforming growth factor beta1 (TGFbeta1) polymorphisms and breast cancer risk. Tumour Biol. 2014;35(5):4757–64.PubMedCrossRef
142.
Zurück zum Zitat Parvizi S, et al. Effects of two common promoter polymorphisms of transforming growth factor-beta1 on breast cancer risks in Ahvaz, west south of Iran. Iran J Cancer Prev. 2016;9(1):e5266.PubMedPubMedCentral Parvizi S, et al. Effects of two common promoter polymorphisms of transforming growth factor-beta1 on breast cancer risks in Ahvaz, west south of Iran. Iran J Cancer Prev. 2016;9(1):e5266.PubMedPubMedCentral
143.
Zurück zum Zitat Tabatabaeian H, Hojati Z. Assessment of HER-2 gene overexpression in Isfahan province breast cancer patients using Real Time RT-PCR and immunohistochemistry. Gene. 2013;531(1):39–43.PubMedCrossRef Tabatabaeian H, Hojati Z. Assessment of HER-2 gene overexpression in Isfahan province breast cancer patients using Real Time RT-PCR and immunohistochemistry. Gene. 2013;531(1):39–43.PubMedCrossRef
144.
Zurück zum Zitat Panahi M, et al. Expressional correlation of human epidermal growth factor receptor 2, estrogen/progesterone receptor and protein 53 in breast cancer. Asian Pac J Cancer Prev. 2013;14(6):3699–703.PubMedCrossRef Panahi M, et al. Expressional correlation of human epidermal growth factor receptor 2, estrogen/progesterone receptor and protein 53 in breast cancer. Asian Pac J Cancer Prev. 2013;14(6):3699–703.PubMedCrossRef
145.
Zurück zum Zitat Amirifard N, et al. Relationship between HER2 proto-oncogene status and prognostic factors of breast cancer in the west of Iran. Asian Pac J Cancer Prev. 2016;17(1):295–8.PubMedCrossRef Amirifard N, et al. Relationship between HER2 proto-oncogene status and prognostic factors of breast cancer in the west of Iran. Asian Pac J Cancer Prev. 2016;17(1):295–8.PubMedCrossRef
146.
Zurück zum Zitat Salimi Z, et al. rs11895168 C allele and the increased risk of breast cancer in Isfahan population. Breast. 2016;28:89–94.PubMedCrossRef Salimi Z, et al. rs11895168 C allele and the increased risk of breast cancer in Isfahan population. Breast. 2016;28:89–94.PubMedCrossRef
147.
Zurück zum Zitat Mansouri Bidkani M, et al. ErbB4 receptor polymorphism 2368A > C and risk of breast cancer. Breast. 2018;42:157–63.PubMedCrossRef Mansouri Bidkani M, et al. ErbB4 receptor polymorphism 2368A > C and risk of breast cancer. Breast. 2018;42:157–63.PubMedCrossRef
148.
Zurück zum Zitat Bagheri F, et al. Tumor-promoting function of single nucleotide polymorphism rs1836724 (C3388T) alters multiple potential legitimate microRNA binding sites at the 3′-untranslated region of ErbB4 in breast cancer. Mol Med Rep. 2016;13(5):4494–8.PubMedCrossRef Bagheri F, et al. Tumor-promoting function of single nucleotide polymorphism rs1836724 (C3388T) alters multiple potential legitimate microRNA binding sites at the 3′-untranslated region of ErbB4 in breast cancer. Mol Med Rep. 2016;13(5):4494–8.PubMedCrossRef
149.
Zurück zum Zitat Normanno N, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16.PubMedCrossRef Normanno N, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16.PubMedCrossRef
150.
Zurück zum Zitat Zhang XM, et al. Expression of tumor related genes NGX6, NAG-7, BRD7 in gastric and colorectal cancer. World J Gastroenterol. 2003;9(8):1729–33.PubMedPubMedCentralCrossRef Zhang XM, et al. Expression of tumor related genes NGX6, NAG-7, BRD7 in gastric and colorectal cancer. World J Gastroenterol. 2003;9(8):1729–33.PubMedPubMedCentralCrossRef
151.
Zurück zum Zitat Wang L, et al. NGX6 gene inhibits cell proliferation and plays a negative role in EGFR pathway in nasopharyngeal carcinoma cells. J Cell Biochem. 2005;95(1):64–73.PubMedCrossRef Wang L, et al. NGX6 gene inhibits cell proliferation and plays a negative role in EGFR pathway in nasopharyngeal carcinoma cells. J Cell Biochem. 2005;95(1):64–73.PubMedCrossRef
152.
Zurück zum Zitat Eskandari-Nasab E, et al. Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer. Mol Biol Rep. 2012;39(12):10531–9.PubMedCrossRef Eskandari-Nasab E, et al. Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer. Mol Biol Rep. 2012;39(12):10531–9.PubMedCrossRef
153.
Zurück zum Zitat Naik A, et al. Neuropilin-1 associated molecules in the blood distinguish poor prognosis breast cancer: a cross-sectional study. Sci Rep. 2017;7(1):3301.PubMedPubMedCentralCrossRef Naik A, et al. Neuropilin-1 associated molecules in the blood distinguish poor prognosis breast cancer: a cross-sectional study. Sci Rep. 2017;7(1):3301.PubMedPubMedCentralCrossRef
154.
Zurück zum Zitat Seifi-Alan M, et al. Neuropilin-1 expression is associated with lymph node metastasis in breast cancer tissues. Cancer Manag Res. 2018;10:1969–74.PubMedPubMedCentralCrossRef Seifi-Alan M, et al. Neuropilin-1 expression is associated with lymph node metastasis in breast cancer tissues. Cancer Manag Res. 2018;10:1969–74.PubMedPubMedCentralCrossRef
155.
Zurück zum Zitat Cleveland RJ, et al. IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis. 2006;27(4):758–65.PubMedCrossRef Cleveland RJ, et al. IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis. 2006;27(4):758–65.PubMedCrossRef
156.
Zurück zum Zitat Javadi M, Hematti S, Tavassoli M. Polymorphic CA repeat length in insulin-like growth factor 1 and risk of breast cancer in Iranian women. Med Oncol. 2012;29(2):516–20.PubMedCrossRef Javadi M, Hematti S, Tavassoli M. Polymorphic CA repeat length in insulin-like growth factor 1 and risk of breast cancer in Iranian women. Med Oncol. 2012;29(2):516–20.PubMedCrossRef
157.
Zurück zum Zitat Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999;253(1):239–54.PubMedCrossRef Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999;253(1):239–54.PubMedCrossRef
158.
Zurück zum Zitat Azizi Tabesh G, et al. The high frequency of PIK3CA mutations in iranian breast cancer patients. Cancer Invest. 2017;35(1):36–42.PubMedCrossRef Azizi Tabesh G, et al. The high frequency of PIK3CA mutations in iranian breast cancer patients. Cancer Invest. 2017;35(1):36–42.PubMedCrossRef
159.
Zurück zum Zitat Sanaei S, et al. KRAS gene polymorphisms and their impact on breast cancer risk in an Iranian population. Asian Pac J Cancer Prev. 2017;18(5):1301–5.PubMedPubMedCentral Sanaei S, et al. KRAS gene polymorphisms and their impact on breast cancer risk in an Iranian population. Asian Pac J Cancer Prev. 2017;18(5):1301–5.PubMedPubMedCentral
160.
Zurück zum Zitat Nazouri AS, et al. High expression of sphingosine kinase 1 in estrogen and progesterone receptors-negative breast cancer. Iran J Pathol. 2017;12(3):218–24.PubMedPubMedCentral Nazouri AS, et al. High expression of sphingosine kinase 1 in estrogen and progesterone receptors-negative breast cancer. Iran J Pathol. 2017;12(3):218–24.PubMedPubMedCentral
161.
Zurück zum Zitat Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer. 2010;10(5):342–52.PubMedCrossRef Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer. 2010;10(5):342–52.PubMedCrossRef
164.
Zurück zum Zitat Heshmatpour N, et al. Association between the lengths of GT dinucleotide repeat in the PIK3CA gene with breast cancer risk. Med Oncol. 2014;31(7):29.PubMedCrossRef Heshmatpour N, et al. Association between the lengths of GT dinucleotide repeat in the PIK3CA gene with breast cancer risk. Med Oncol. 2014;31(7):29.PubMedCrossRef
165.
Zurück zum Zitat Ghalaei A, et al. Overexpressed in colorectal carcinoma gene (OCC-1) upregulation and APPL2 gene downregulation in breast cancer specimens. Mol Biol Rep. 2018;45(6):1889–95.PubMedCrossRef Ghalaei A, et al. Overexpressed in colorectal carcinoma gene (OCC-1) upregulation and APPL2 gene downregulation in breast cancer specimens. Mol Biol Rep. 2018;45(6):1889–95.PubMedCrossRef
166.
Zurück zum Zitat Karami-Tehrani F, et al. Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors. Tumour Biol. 2016;37(7):8849–56.PubMedCrossRef Karami-Tehrani F, et al. Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors. Tumour Biol. 2016;37(7):8849–56.PubMedCrossRef
167.
Zurück zum Zitat Lipkowitz S. The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res. 2003;5(1):8–15.PubMedCrossRef Lipkowitz S. The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res. 2003;5(1):8–15.PubMedCrossRef
168.
Zurück zum Zitat Nikseresht M, et al. Overexpression of the novel human gene, UBE2Q2, in breast cancer. Cancer Genet Cytogenet. 2010;197(2):101–6.PubMedCrossRef Nikseresht M, et al. Overexpression of the novel human gene, UBE2Q2, in breast cancer. Cancer Genet Cytogenet. 2010;197(2):101–6.PubMedCrossRef
169.
Zurück zum Zitat Vogl FD, et al. Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev. 2004;13(9):1473–9.PubMed Vogl FD, et al. Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev. 2004;13(9):1473–9.PubMed
170.
Zurück zum Zitat Hashemi M, et al. Association between polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer risk in a sample Iranian population. Biomark Med. 2012;6(6):797–803.PubMedCrossRef Hashemi M, et al. Association between polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer risk in a sample Iranian population. Biomark Med. 2012;6(6):797–803.PubMedCrossRef
171.
Zurück zum Zitat Sharif MR, et al. Association of GSTO1 A140D and GSTO2 N142D gene variations with breast cancer risk. Asian Pac J Cancer Prev. 2017;18(6):1723–7.PubMedPubMedCentral Sharif MR, et al. Association of GSTO1 A140D and GSTO2 N142D gene variations with breast cancer risk. Asian Pac J Cancer Prev. 2017;18(6):1723–7.PubMedPubMedCentral
172.
Zurück zum Zitat Petersen DD, et al. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet. 1991;48(4):720–5.PubMedPubMedCentral Petersen DD, et al. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet. 1991;48(4):720–5.PubMedPubMedCentral
173.
Zurück zum Zitat Saadatian H, et al. Polymorphism of the cytochrome P-450 1A1 (A2455G) in women with breast cancer in Eastern Azerbaijan, Iran. Iran J Basic Med Sci. 2014;17(3):227–30.PubMedPubMedCentral Saadatian H, et al. Polymorphism of the cytochrome P-450 1A1 (A2455G) in women with breast cancer in Eastern Azerbaijan, Iran. Iran J Basic Med Sci. 2014;17(3):227–30.PubMedPubMedCentral
174.
Zurück zum Zitat Saghafi F, et al. CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen. Biomed Rep. 2018;9(5):446–52.PubMedPubMedCentral Saghafi F, et al. CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen. Biomed Rep. 2018;9(5):446–52.PubMedPubMedCentral
175.
Zurück zum Zitat Darakhshan S, et al. Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells. Asian Pac J Cancer Prev. 2013;14(11):6869–74.PubMedCrossRef Darakhshan S, et al. Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells. Asian Pac J Cancer Prev. 2013;14(11):6869–74.PubMedCrossRef
176.
Zurück zum Zitat Motamedi S, et al. Tamoxifen resistance and CYP2D6 copy numbers in breast cancer patients. Asian Pac J Cancer Prev. 2012;13(12):6101–4.PubMedCrossRef Motamedi S, et al. Tamoxifen resistance and CYP2D6 copy numbers in breast cancer patients. Asian Pac J Cancer Prev. 2012;13(12):6101–4.PubMedCrossRef
177.
Zurück zum Zitat Meiyanto E, Hermawan A, Anindyajati A. Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pac J Cancer Prev. 2012;13(2):427–36.PubMedCrossRef Meiyanto E, Hermawan A, Anindyajati A. Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pac J Cancer Prev. 2012;13(2):427–36.PubMedCrossRef
178.
Zurück zum Zitat Lash TL, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst. 2011;103(6):489–500.PubMedPubMedCentralCrossRef Lash TL, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst. 2011;103(6):489–500.PubMedPubMedCentralCrossRef
179.
Zurück zum Zitat Yazdi MF, et al. CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients. Asian Pac J Cancer Prev. 2015;16(15):6783–7.PubMedCrossRef Yazdi MF, et al. CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients. Asian Pac J Cancer Prev. 2015;16(15):6783–7.PubMedCrossRef
180.
Zurück zum Zitat Ciocca DR, et al. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst. 1993;85(19):1558–70.PubMedCrossRef Ciocca DR, et al. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst. 1993;85(19):1558–70.PubMedCrossRef
181.
Zurück zum Zitat Mehlen P, et al. Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. J Immunol. 1995;154(1):363–74.PubMed Mehlen P, et al. Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. J Immunol. 1995;154(1):363–74.PubMed
182.
Zurück zum Zitat Calderwood SK, et al. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006;31(3):164–72.PubMedCrossRef Calderwood SK, et al. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006;31(3):164–72.PubMedCrossRef
183.
Zurück zum Zitat Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair. 2012;5(1):7.PubMedPubMedCentralCrossRef Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair. 2012;5(1):7.PubMedPubMedCentralCrossRef
184.
Zurück zum Zitat Homaei-Shandiz F, et al. Anti-heat shock protein-27 antibody levels in women with breast cancer: association with disease complications and two-year disease-free survival. Asian Pac J Cancer Prev. 2016;17(10):4655–9.PubMedPubMedCentral Homaei-Shandiz F, et al. Anti-heat shock protein-27 antibody levels in women with breast cancer: association with disease complications and two-year disease-free survival. Asian Pac J Cancer Prev. 2016;17(10):4655–9.PubMedPubMedCentral
185.
Zurück zum Zitat Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol. 2014;10(10):1337–54.PubMedCrossRef Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol. 2014;10(10):1337–54.PubMedCrossRef
186.
Zurück zum Zitat Durmus S, Hendrikx JJ, Schinkel AH. Apical ABC transporters and cancer chemotherapeutic drug disposition. Adv Cancer Res. 2015;125:1–41.PubMedCrossRef Durmus S, Hendrikx JJ, Schinkel AH. Apical ABC transporters and cancer chemotherapeutic drug disposition. Adv Cancer Res. 2015;125:1–41.PubMedCrossRef
187.
Zurück zum Zitat Ghafouri H, et al. Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer. Tumour Biol. 2016;37(6):7901–6.PubMedCrossRef Ghafouri H, et al. Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer. Tumour Biol. 2016;37(6):7901–6.PubMedCrossRef
188.
Zurück zum Zitat Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32(3–4):643–71.PubMedCrossRef Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32(3–4):643–71.PubMedCrossRef
189.
Zurück zum Zitat Estiar MA, et al. High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer. Clin Exp Med. 2017;17(4):547–53.PubMedCrossRef Estiar MA, et al. High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer. Clin Exp Med. 2017;17(4):547–53.PubMedCrossRef
190.
Zurück zum Zitat Thriveni K, Krishnamoorthy L, Ramaswamy G. Correlation study of Carcino Embryonic Antigen & Cancer Antigen 15.3 in pretreated female breast cancer patients. Indian J Clin Biochem. 2007;22(1):57–60.PubMedPubMedCentralCrossRef Thriveni K, Krishnamoorthy L, Ramaswamy G. Correlation study of Carcino Embryonic Antigen & Cancer Antigen 15.3 in pretreated female breast cancer patients. Indian J Clin Biochem. 2007;22(1):57–60.PubMedPubMedCentralCrossRef
191.
Zurück zum Zitat Duffy MJ. CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem. 1999;36(Pt 5):579–86.PubMedCrossRef Duffy MJ. CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem. 1999;36(Pt 5):579–86.PubMedCrossRef
192.
Zurück zum Zitat Moazzezy N, et al. Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pac J Cancer Prev. 2014;15(4):1685–8.PubMedCrossRef Moazzezy N, et al. Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pac J Cancer Prev. 2014;15(4):1685–8.PubMedCrossRef
193.
Zurück zum Zitat Mansouri N, et al. Overexpression of the MUC1 gene in Iranian women with breast cancer micrometastasis. Asian Pac J Cancer Prev. 2016;17(S3):275–8.PubMedCrossRef Mansouri N, et al. Overexpression of the MUC1 gene in Iranian women with breast cancer micrometastasis. Asian Pac J Cancer Prev. 2016;17(S3):275–8.PubMedCrossRef
194.
Zurück zum Zitat Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol. 2005;6(8):622–34.PubMedCrossRef Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol. 2005;6(8):622–34.PubMedCrossRef
195.
Zurück zum Zitat Tepass U, et al. Cadherins in embryonic and neural morphogenesis. Nat Rev Mol Cell Biol. 2000;1(2):91–100.PubMedCrossRef Tepass U, et al. Cadherins in embryonic and neural morphogenesis. Nat Rev Mol Cell Biol. 2000;1(2):91–100.PubMedCrossRef
196.
Zurück zum Zitat Zarei F, et al. Higher risk of progressing breast cancer in Kurdish population associated to CDH1 -160 C/A polymorphism. EXCLI J. 2017;16:1198–205.PubMedPubMedCentral Zarei F, et al. Higher risk of progressing breast cancer in Kurdish population associated to CDH1 -160 C/A polymorphism. EXCLI J. 2017;16:1198–205.PubMedPubMedCentral
197.
Zurück zum Zitat Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319.PubMedCrossRef Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319.PubMedCrossRef
198.
Zurück zum Zitat Esmaeili R, et al. Unique CD44 intronic SNP is associated with tumor grade in breast cancer: a case control study and in silico analysis. Cancer Cell Int. 2018;18:28.PubMedPubMedCentralCrossRef Esmaeili R, et al. Unique CD44 intronic SNP is associated with tumor grade in breast cancer: a case control study and in silico analysis. Cancer Cell Int. 2018;18:28.PubMedPubMedCentralCrossRef
199.
Zurück zum Zitat Maetzel D, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009;11(2):162–71.PubMedCrossRef Maetzel D, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009;11(2):162–71.PubMedCrossRef
200.
Zurück zum Zitat Gottlinger HG, et al. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer. 1986;38(1):47–53.PubMedCrossRef Gottlinger HG, et al. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer. 1986;38(1):47–53.PubMedCrossRef
201.
202.
Zurück zum Zitat Sadeghi S, Hojati Z, Tabatabaeian H. Cooverexpression of EpCAM and c-myc genes in malignant breast tumours. J Genet. 2017;96(1):109–18.PubMedCrossRef Sadeghi S, Hojati Z, Tabatabaeian H. Cooverexpression of EpCAM and c-myc genes in malignant breast tumours. J Genet. 2017;96(1):109–18.PubMedCrossRef
203.
Zurück zum Zitat Maguer-Satta V, Besancon R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells. 2011;29(3):389–96.PubMedCrossRef Maguer-Satta V, Besancon R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells. 2011;29(3):389–96.PubMedCrossRef
204.
Zurück zum Zitat Taghizadeh-Kermani A, et al. The stromal overexpression of CD10 in invasive breast cancer and its association with clincophathologic factors. Iran J Cancer Prev. 2014;7(1):17–21.PubMedPubMedCentral Taghizadeh-Kermani A, et al. The stromal overexpression of CD10 in invasive breast cancer and its association with clincophathologic factors. Iran J Cancer Prev. 2014;7(1):17–21.PubMedPubMedCentral
206.
Zurück zum Zitat Williams TM, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem. 2004;279(49):51630–46.PubMedCrossRef Williams TM, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem. 2004;279(49):51630–46.PubMedCrossRef
207.
Zurück zum Zitat Fard ZT, Nafisi N. The relationship between 6 polymorphisms of Caveolin-1 gene and the risk of breast cancer. Clin Breast Cancer. 2018;18(5):e893–8.PubMedCrossRef Fard ZT, Nafisi N. The relationship between 6 polymorphisms of Caveolin-1 gene and the risk of breast cancer. Clin Breast Cancer. 2018;18(5):e893–8.PubMedCrossRef
208.
Zurück zum Zitat Mobasheri MB, Shirkoohi R, Modarressi MH. Synaptonemal complex protein 3 transcript analysis in breast cancer. Iran J Public Health. 2016;45(12):1618–24.PubMedPubMedCentral Mobasheri MB, Shirkoohi R, Modarressi MH. Synaptonemal complex protein 3 transcript analysis in breast cancer. Iran J Public Health. 2016;45(12):1618–24.PubMedPubMedCentral
209.
Zurück zum Zitat Malek-Hosseini Z, et al. Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size. Breast Cancer. 2017;24(6):742–7.PubMedCrossRef Malek-Hosseini Z, et al. Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size. Breast Cancer. 2017;24(6):742–7.PubMedCrossRef
210.
Zurück zum Zitat Rehman G, et al. Role of AMP-activated protein kinase in cancer therapy. Arch Pharm (Weinheim). 2014;347(7):457–68.CrossRef Rehman G, et al. Role of AMP-activated protein kinase in cancer therapy. Arch Pharm (Weinheim). 2014;347(7):457–68.CrossRef
211.
Zurück zum Zitat Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75(4):725–48.PubMedCrossRef Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75(4):725–48.PubMedCrossRef
212.
Zurück zum Zitat Lincoln TM, Cornwell TL. Intracellular cyclic GMP receptor proteins. FASEB J. 1993;7(2):328–38.PubMedCrossRef Lincoln TM, Cornwell TL. Intracellular cyclic GMP receptor proteins. FASEB J. 1993;7(2):328–38.PubMedCrossRef
213.
Zurück zum Zitat Karami-Tehrani F, et al. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res. 2012;43(6):470–5.PubMedCrossRef Karami-Tehrani F, et al. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res. 2012;43(6):470–5.PubMedCrossRef
214.
Zurück zum Zitat Fiscus RR, Murad F. cGMP-dependent protein kinase activation in intact tissues. Methods Enzymol. 1988;159:150–9.PubMedCrossRef Fiscus RR, Murad F. cGMP-dependent protein kinase activation in intact tissues. Methods Enzymol. 1988;159:150–9.PubMedCrossRef
215.
Zurück zum Zitat Karami-Tehrani F, Fallahian F, Atri M. Expression of cGMP-dependent protein kinase, PKGIalpha, PKGIbeta, and PKGII in malignant and benign breast tumors. Tumour Biol. 2012;33(6):1927–32.PubMedCrossRef Karami-Tehrani F, Fallahian F, Atri M. Expression of cGMP-dependent protein kinase, PKGIalpha, PKGIbeta, and PKGII in malignant and benign breast tumors. Tumour Biol. 2012;33(6):1927–32.PubMedCrossRef
216.
217.
Zurück zum Zitat Moghbeli M, et al. Role of Msi1 and MAML1 in regulation of notch signaling pathway in patients with esophageal squamous cell carcinoma. J Gastrointest Cancer. 2015;46(4):365–9.PubMedCrossRef Moghbeli M, et al. Role of Msi1 and MAML1 in regulation of notch signaling pathway in patients with esophageal squamous cell carcinoma. J Gastrointest Cancer. 2015;46(4):365–9.PubMedCrossRef
219.
Zurück zum Zitat Moghbeli M, et al. Role of Msi1 and PYGO2 in esophageal squamous cell carcinoma depth of invasion. J Cell Commun Signal. 2016;10(1):49–53.PubMedCrossRef Moghbeli M, et al. Role of Msi1 and PYGO2 in esophageal squamous cell carcinoma depth of invasion. J Cell Commun Signal. 2016;10(1):49–53.PubMedCrossRef
220.
Zurück zum Zitat Taghavi A, et al. Gene expression profiling of the 8q22-24 position in human breast cancer: TSPYL5, MTDH, ATAD2 and CCNE2 genes are implicated in oncogenesis, while WISP1 and EXT1 genes may predict a risk of metastasis. Oncol Lett. 2016;12(5):3845–55.PubMedPubMedCentralCrossRef Taghavi A, et al. Gene expression profiling of the 8q22-24 position in human breast cancer: TSPYL5, MTDH, ATAD2 and CCNE2 genes are implicated in oncogenesis, while WISP1 and EXT1 genes may predict a risk of metastasis. Oncol Lett. 2016;12(5):3845–55.PubMedPubMedCentralCrossRef
221.
222.
Zurück zum Zitat Balicki D. Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell. 2007;1(5):485–7.PubMedCrossRef Balicki D. Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell. 2007;1(5):485–7.PubMedCrossRef
223.
Zurück zum Zitat Ginestier C, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.PubMedPubMedCentralCrossRef Ginestier C, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.PubMedPubMedCentralCrossRef
224.
Zurück zum Zitat Madjd Z, et al. High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas. Asian Pac J Cancer Prev. 2012;13(6):2973–8.PubMedCrossRef Madjd Z, et al. High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas. Asian Pac J Cancer Prev. 2012;13(6):2973–8.PubMedCrossRef
225.
Zurück zum Zitat Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis. 2001;6(6):469–77.PubMedCrossRef Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis. 2001;6(6):469–77.PubMedCrossRef
226.
Zurück zum Zitat Yu FL, Bender W. A proposed mechanism of tamoxifen in breast cancer prevention. Cancer Detect Prev. 2002;26(5):370–5.PubMedCrossRef Yu FL, Bender W. A proposed mechanism of tamoxifen in breast cancer prevention. Cancer Detect Prev. 2002;26(5):370–5.PubMedCrossRef
227.
Zurück zum Zitat Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–43.PubMedCrossRef Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–43.PubMedCrossRef
228.
Zurück zum Zitat Eccles MR, et al. PAX genes in development and disease: the role of PAX2 in urogenital tract development. Int J Dev Biol. 2002;46(4):535–44.PubMed Eccles MR, et al. PAX genes in development and disease: the role of PAX2 in urogenital tract development. Int J Dev Biol. 2002;46(4):535–44.PubMed
229.
Zurück zum Zitat Jahangiri R, et al. PAX2 expression is correlated with better survival in tamoxifen-treated breast carcinoma patients. Tissue Cell. 2018;52:135–42.PubMedCrossRef Jahangiri R, et al. PAX2 expression is correlated with better survival in tamoxifen-treated breast carcinoma patients. Tissue Cell. 2018;52:135–42.PubMedCrossRef
230.
Zurück zum Zitat Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem. 2006;281(46):34725–9.PubMedCrossRef Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem. 2006;281(46):34725–9.PubMedCrossRef
231.
Zurück zum Zitat Qu X, et al. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem. 2002;229(1–2):35–44.PubMedCrossRef Qu X, et al. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem. 2002;229(1–2):35–44.PubMedCrossRef
232.
Zurück zum Zitat Zhao W, et al. Cloning and expression pattern of the human NDRG3 gene. Biochim Biophys Acta. 2001;1519(1–2):134–8.PubMedCrossRef Zhao W, et al. Cloning and expression pattern of the human NDRG3 gene. Biochim Biophys Acta. 2001;1519(1–2):134–8.PubMedCrossRef
233.
Zurück zum Zitat Estiar MA, et al. Clinical significance of NDRG3 in patients with breast cancer. Future Oncol. 2017;13(11):961–9.PubMedCrossRef Estiar MA, et al. Clinical significance of NDRG3 in patients with breast cancer. Future Oncol. 2017;13(11):961–9.PubMedCrossRef
234.
Zurück zum Zitat Hosseini A, et al. Estrogen receptor alpha gene expression in breast cancer tissues from the Iranian population–a pilot study. Asian Pac J Cancer Prev. 2014;15(20):8789–91.PubMedCrossRef Hosseini A, et al. Estrogen receptor alpha gene expression in breast cancer tissues from the Iranian populationa pilot study. Asian Pac J Cancer Prev. 2014;15(20):8789–91.PubMedCrossRef
235.
Zurück zum Zitat Abbasi S, et al. Association of estrogen receptor-alpha A908G (K303R) mutation with breast cancer risk. Int J Clin Exp Med. 2013;6(1):39–49.PubMed Abbasi S, et al. Association of estrogen receptor-alpha A908G (K303R) mutation with breast cancer risk. Int J Clin Exp Med. 2013;6(1):39–49.PubMed
236.
Zurück zum Zitat Farzaneh F, et al. Analysis of CYP17, CYP19 and CYP1A1 Gene polymorphisms in Iranian women with breast cancer. Asian Pac J Cancer Prev. 2016;17(S3):23–6.PubMedCrossRef Farzaneh F, et al. Analysis of CYP17, CYP19 and CYP1A1 Gene polymorphisms in Iranian women with breast cancer. Asian Pac J Cancer Prev. 2016;17(S3):23–6.PubMedCrossRef
237.
Zurück zum Zitat Duncan LJ, Coldham NG, Reed MJ. The interaction of cytokines in regulating oestradiol 17 beta-hydroxysteroid dehydrogenase activity in MCF-7 cells. J Steroid Biochem Mol Biol. 1994;49(1):63–8.PubMedCrossRef Duncan LJ, Coldham NG, Reed MJ. The interaction of cytokines in regulating oestradiol 17 beta-hydroxysteroid dehydrogenase activity in MCF-7 cells. J Steroid Biochem Mol Biol. 1994;49(1):63–8.PubMedCrossRef
238.
Zurück zum Zitat Newman SP, et al. Regulation of steroid sulphatase expression and activity in breast cancer. J Steroid Biochem Mol Biol. 2000;75(4–5):259–64.PubMedCrossRef Newman SP, et al. Regulation of steroid sulphatase expression and activity in breast cancer. J Steroid Biochem Mol Biol. 2000;75(4–5):259–64.PubMedCrossRef
239.
Zurück zum Zitat Danforth DN, Sgagias MK. Tumour necrosis factor-alpha modulates oestradiol responsiveness of MCF-7 breast cancer cells in vitro. J Endocrinol. 1993;138(3):517–28.PubMedCrossRef Danforth DN, Sgagias MK. Tumour necrosis factor-alpha modulates oestradiol responsiveness of MCF-7 breast cancer cells in vitro. J Endocrinol. 1993;138(3):517–28.PubMedCrossRef
240.
Zurück zum Zitat Roodi N, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst. 1995;87(6):446–51.PubMedCrossRef Roodi N, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst. 1995;87(6):446–51.PubMedCrossRef
241.
Zurück zum Zitat Kamali-Sarvestani E, et al. Association of TNF-alpha and TNF-beta gene polymorphism with steroid receptor expression in breast cancer patients. Pathol Oncol Res. 2005;11(2):99–102.PubMedCrossRef Kamali-Sarvestani E, et al. Association of TNF-alpha and TNF-beta gene polymorphism with steroid receptor expression in breast cancer patients. Pathol Oncol Res. 2005;11(2):99–102.PubMedCrossRef
242.
Zurück zum Zitat Di C, et al. Basophil-associated OX40 ligand participates in the initiation of Th2 responses during airway inflammation. J Biol Chem. 2015;290(20):12523–36.PubMedPubMedCentralCrossRef Di C, et al. Basophil-associated OX40 ligand participates in the initiation of Th2 responses during airway inflammation. J Biol Chem. 2015;290(20):12523–36.PubMedPubMedCentralCrossRef
243.
Zurück zum Zitat Lee J, et al. Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology. 2008;125(2):229–40.PubMedPubMedCentralCrossRef Lee J, et al. Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology. 2008;125(2):229–40.PubMedPubMedCentralCrossRef
244.
Zurück zum Zitat Ohshima Y, et al. Expression and function of OX40 ligand on human dendritic cells. J Immunol. 1997;159(8):3838–48.PubMed Ohshima Y, et al. Expression and function of OX40 ligand on human dendritic cells. J Immunol. 1997;159(8):3838–48.PubMed
245.
Zurück zum Zitat Vakil R, Mashayekhi F. OX40L gene polymorphism and breast cancer in Iranian population. Exp Oncol. 2018;40(2):132–5.CrossRef Vakil R, Mashayekhi F. OX40L gene polymorphism and breast cancer in Iranian population. Exp Oncol. 2018;40(2):132–5.CrossRef
246.
Zurück zum Zitat Crew KD. Vitamin d: are we ready to supplement for breast cancer prevention and treatment? ISRN Oncol. 2013;2013:483687.PubMedPubMedCentral Crew KD. Vitamin d: are we ready to supplement for breast cancer prevention and treatment? ISRN Oncol. 2013;2013:483687.PubMedPubMedCentral
247.
Zurück zum Zitat Jurutka PW, et al. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord. 2001;2(2):203–16.PubMedCrossRef Jurutka PW, et al. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord. 2001;2(2):203–16.PubMedCrossRef
248.
249.
Zurück zum Zitat Barsony J, Prufer K. Vitamin D receptor and retinoid X receptor interactions in motion. Vitam Horm. 2002;65:345–76.PubMedCrossRef Barsony J, Prufer K. Vitamin D receptor and retinoid X receptor interactions in motion. Vitam Horm. 2002;65:345–76.PubMedCrossRef
250.
Zurück zum Zitat Colagar AH, Firouzjah HM, Halalkhor S. Vitamin D Receptor Poly(A) Microsatellite Polymorphism and 25-Hydroxyvitamin D Serum Levels: association with Susceptibility to Breast Cancer. J Breast Cancer. 2015;18(2):119–25.PubMedPubMedCentralCrossRef Colagar AH, Firouzjah HM, Halalkhor S. Vitamin D Receptor Poly(A) Microsatellite Polymorphism and 25-Hydroxyvitamin D Serum Levels: association with Susceptibility to Breast Cancer. J Breast Cancer. 2015;18(2):119–25.PubMedPubMedCentralCrossRef
251.
Zurück zum Zitat Anderson MG, et al. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol. 2006;57(2):234–40.PubMedCrossRef Anderson MG, et al. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol. 2006;57(2):234–40.PubMedCrossRef
252.
Zurück zum Zitat Anderson PH, et al. Quantification of mRNA for the vitamin D metabolizing enzymes CYP27B1 and CYP24 and vitamin D receptor in kidney using real-time reverse transcriptase- polymerase chain reaction. J Mol Endocrinol. 2003;31(1):123–32.PubMedCrossRef Anderson PH, et al. Quantification of mRNA for the vitamin D metabolizing enzymes CYP27B1 and CYP24 and vitamin D receptor in kidney using real-time reverse transcriptase- polymerase chain reaction. J Mol Endocrinol. 2003;31(1):123–32.PubMedCrossRef
253.
Zurück zum Zitat Haussler MR, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int. 2013;92(2):77–98.PubMedCrossRef Haussler MR, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int. 2013;92(2):77–98.PubMedCrossRef
254.
Zurück zum Zitat Horvath HC, et al. The candidate oncogene CYP24A1: a potential biomarker for colorectal tumorigenesis. J Histochem Cytochem. 2010;58(3):277–85.PubMedPubMedCentralCrossRef Horvath HC, et al. The candidate oncogene CYP24A1: a potential biomarker for colorectal tumorigenesis. J Histochem Cytochem. 2010;58(3):277–85.PubMedPubMedCentralCrossRef
255.
Zurück zum Zitat Zhalehjoo N, Shakiba Y, Panjehpour M. Gene expression profiles of CYP24A1 and CYP27B1 in malignant and normal breast tissues. Mol Med Rep. 2017;15(1):467–73.PubMedCrossRef Zhalehjoo N, Shakiba Y, Panjehpour M. Gene expression profiles of CYP24A1 and CYP27B1 in malignant and normal breast tissues. Mol Med Rep. 2017;15(1):467–73.PubMedCrossRef
256.
Zurück zum Zitat Shahabi A, et al. Vitamin D receptor gene polymorphism: association with susceptibility to early-onset breast cancer in Iranian, BRCA1/2-mutation carrier and non-carrier patients. Pathol Oncol Res. 2018;24(3):601–7.PubMedCrossRef Shahabi A, et al. Vitamin D receptor gene polymorphism: association with susceptibility to early-onset breast cancer in Iranian, BRCA1/2-mutation carrier and non-carrier patients. Pathol Oncol Res. 2018;24(3):601–7.PubMedCrossRef
257.
Zurück zum Zitat Shahbazi S, et al. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Med Oncol. 2013;30(1):393.PubMedCrossRef Shahbazi S, et al. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Med Oncol. 2013;30(1):393.PubMedCrossRef
258.
Zurück zum Zitat Reid AH, et al. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol. 2008;5(11):610–20.PubMedCrossRef Reid AH, et al. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol. 2008;5(11):610–20.PubMedCrossRef
259.
Zurück zum Zitat Setiawan VW, et al. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev. 2007;16(11):2237–46.PubMedCrossRef Setiawan VW, et al. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev. 2007;16(11):2237–46.PubMedCrossRef
260.
Zurück zum Zitat Ebrahimi E, et al. CYP17 MspA1 gene polymorphism and breast cancer patients according to age of onset in cancer institute of Iran. Iran J Public Health. 2017;46(4):537–44.PubMedPubMedCentral Ebrahimi E, et al. CYP17 MspA1 gene polymorphism and breast cancer patients according to age of onset in cancer institute of Iran. Iran J Public Health. 2017;46(4):537–44.PubMedPubMedCentral
261.
Zurück zum Zitat Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1.PubMed Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1.PubMed
262.
Zurück zum Zitat Salmaninejad A, et al. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest. 2016;45(7):619–40.PubMedCrossRef Salmaninejad A, et al. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest. 2016;45(7):619–40.PubMedCrossRef
263.
264.
Zurück zum Zitat Lim SK, et al. Tyrosine phosphorylation of transcriptional coactivator WW-domain binding protein 2 regulates estrogen receptor alpha function in breast cancer via the Wnt pathway. FASEB J. 2011;25(9):3004–18.PubMedCrossRef Lim SK, et al. Tyrosine phosphorylation of transcriptional coactivator WW-domain binding protein 2 regulates estrogen receptor alpha function in breast cancer via the Wnt pathway. FASEB J. 2011;25(9):3004–18.PubMedCrossRef
265.
Zurück zum Zitat Nourashrafeddin S, et al. Expression analysis of PAWP during mouse embryonic stem cell-based spermatogenesis in vitro. Vitro Cell Dev Biol Anim. 2014;50(5):475–81.CrossRef Nourashrafeddin S, et al. Expression analysis of PAWP during mouse embryonic stem cell-based spermatogenesis in vitro. Vitro Cell Dev Biol Anim. 2014;50(5):475–81.CrossRef
266.
267.
Zurück zum Zitat Rastgoosalami M, et al. Evaluation of MAGE-1 cancer-testis antigen expression in invasive breast cancer and its correlation with prognostic factors. Iran J Cancer Prev. 2016;9(4):e4404.PubMedPubMedCentralCrossRef Rastgoosalami M, et al. Evaluation of MAGE-1 cancer-testis antigen expression in invasive breast cancer and its correlation with prognostic factors. Iran J Cancer Prev. 2016;9(4):e4404.PubMedPubMedCentralCrossRef
268.
269.
Zurück zum Zitat Nakagawa Y, et al. Outer dense fiber 2 is a widespread centrosome scaffold component preferentially associated with mother centrioles: its identification from isolated centrosomes. Mol Biol Cell. 2001;12(6):1687–97.PubMedPubMedCentralCrossRef Nakagawa Y, et al. Outer dense fiber 2 is a widespread centrosome scaffold component preferentially associated with mother centrioles: its identification from isolated centrosomes. Mol Biol Cell. 2001;12(6):1687–97.PubMedPubMedCentralCrossRef
270.
Zurück zum Zitat Shibata-Minoshima F, et al. Identification of RHOXF2 (PEPP2) as a cancer-promoting gene by expression cloning. Int J Oncol. 2012;40(1):93–8.PubMed Shibata-Minoshima F, et al. Identification of RHOXF2 (PEPP2) as a cancer-promoting gene by expression cloning. Int J Oncol. 2012;40(1):93–8.PubMed
271.
Zurück zum Zitat Zou Y, Zhong W. A likely role for a novel PH-domain containing protein, PEPP2, in connecting membrane and cytoskeleton. Biocell. 2012;36(3):127–32.PubMed Zou Y, Zhong W. A likely role for a novel PH-domain containing protein, PEPP2, in connecting membrane and cytoskeleton. Biocell. 2012;36(3):127–32.PubMed
272.
Zurück zum Zitat Kazemi-Oula G, et al. Upregulation of RHOXF2 and ODF4 expression in breast cancer tissues. Cell J. 2015;17(3):471–7.PubMedPubMedCentral Kazemi-Oula G, et al. Upregulation of RHOXF2 and ODF4 expression in breast cancer tissues. Cell J. 2015;17(3):471–7.PubMedPubMedCentral
273.
Zurück zum Zitat Hsu CC, Tseng LM, Lee HC. Role of mitochondrial dysfunction in cancer progression. Exp Biol Med (Maywood). 2016;241(12):1281–95.CrossRef Hsu CC, Tseng LM, Lee HC. Role of mitochondrial dysfunction in cancer progression. Exp Biol Med (Maywood). 2016;241(12):1281–95.CrossRef
275.
Zurück zum Zitat Yadav N, Chandra D. Mitochondrial DNA mutations and breast tumorigenesis. Biochim Biophys Acta. 2013;1836(2):336–44.PubMedPubMedCentral Yadav N, Chandra D. Mitochondrial DNA mutations and breast tumorigenesis. Biochim Biophys Acta. 2013;1836(2):336–44.PubMedPubMedCentral
276.
Zurück zum Zitat Damm F, et al. Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia. Leukemia. 2012;26(2):289–95.PubMedCrossRef Damm F, et al. Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia. Leukemia. 2012;26(2):289–95.PubMedCrossRef
277.
Zurück zum Zitat Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol. 2008;18(4):165–73.PubMedCrossRef Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol. 2008;18(4):165–73.PubMedCrossRef
278.
Zurück zum Zitat Arezi P, Rezvani Z. The variation of mitochondrial NADH dehydrogenase subunit 4 (mtND4) and molecular dynamics simulation of SNPs among Iranian women with breast cancer. J Mol Graph Model. 2018;85:242–9.PubMedCrossRef Arezi P, Rezvani Z. The variation of mitochondrial NADH dehydrogenase subunit 4 (mtND4) and molecular dynamics simulation of SNPs among Iranian women with breast cancer. J Mol Graph Model. 2018;85:242–9.PubMedCrossRef
279.
Zurück zum Zitat Czarnecka AM, et al. Mitochondrial DNA mutations in cancer–from bench to bedside. Front Biosci (Landmark Ed). 2010;15:437–60.CrossRef Czarnecka AM, et al. Mitochondrial DNA mutations in cancer–from bench to bedside. Front Biosci (Landmark Ed). 2010;15:437–60.CrossRef
280.
Zurück zum Zitat Park JS, et al. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet. 2009;18(9):1578–89.PubMedPubMedCentralCrossRef Park JS, et al. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet. 2009;18(9):1578–89.PubMedPubMedCentralCrossRef
281.
Zurück zum Zitat Jonckheere AI, Smeitink JA, Rodenburg RJ. Mitochondrial ATP synthase: architecture, function and pathology. J Inherit Metab Dis. 2012;35(2):211–25.PubMedCrossRef Jonckheere AI, Smeitink JA, Rodenburg RJ. Mitochondrial ATP synthase: architecture, function and pathology. J Inherit Metab Dis. 2012;35(2):211–25.PubMedCrossRef
282.
Zurück zum Zitat Ghaffarpour M, et al. The mitochondrial ATPase6 gene is more susceptible to mutation than the ATPase8 gene in breast cancer patients. Cancer Cell Int. 2014;14(1):21.PubMedPubMedCentralCrossRef Ghaffarpour M, et al. The mitochondrial ATPase6 gene is more susceptible to mutation than the ATPase8 gene in breast cancer patients. Cancer Cell Int. 2014;14(1):21.PubMedPubMedCentralCrossRef
Metadaten
Titel
Genetic and molecular biology of breast cancer among Iranian patients
verfasst von
Meysam Moghbeli
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
Journal of Translational Medicine / Ausgabe 1/2019
Elektronische ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-019-1968-2

Weitere Artikel der Ausgabe 1/2019

Journal of Translational Medicine 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.